



# Market snapshot



áil

Equities - India	Close	Chg .%	YTD.%
Sensex	31,568	0.9	18.6
Nifty-50	9,853	0.9	20.4
Nifty-M 100	17,857	1.2	24.4
<b>Equities-Global</b>	Close	Chg .%	YTD.%
S&P 500	2,444	-0.3	9.2
Nasdaq	6,278	-0.3	16.6
FTSE 100	7,383	0.0	3.4
DAX	12,174	-0.5	6.0
Hang Seng	10,955	0.0	16.6
Nikkei 225	19,435	0.3	1.7
Commodities	Close	Chg .%	YTD.%
Brent (US\$/Bbl)	52	1.3	-6.5
Gold (\$/OZ)	1,287	0.1	11.0
Cu (US\$/MT)	6,537	-0.2	18.4
Almn (US\$/MT)	2,101	0.7	23.3
Currency	Close	Chg .%	YTD.%
USD/INR	64.1	0.0	-5.5
USD/EUR	1.2	0.2	11.7
USD/JPY	109.5	0.1	-6.5
YIELD (%)	Close	1MChg	YTDchg
10 Yrs G-Sec	6.5	0.0	0.0
10 Yrs AAA Corp	7.5	0.0	-0.1
Flows (USD b)	23-Aug	MTD	YTD
FIIs	-0.1	-2.0	6.8
DIIs	0.1	2.0	6.0
Volumes (INRb)	23-Aug	MTD*	YTD*
Cash	269	304	289
F&O	7,159	6,631	5,200

Note: YTD is calendar year, \*Avg

# Today's top research idea

# Trident - Initiating Coverage: An attractive utilization play

- TRID is set to deliver CAGR of 9% in revenue and 24% in earnings over FY17-20, driven by revenue CAGR of 44% in bed linen and 12% in bath linen.
- The recently ventured bed linen segment is expected to turn EBITDA profitable by 3QFY18 as utilization touches 40%. The segment's share in overall revenue should increase from 4% in FY17 to 9% in FY20.
- After significant capacity expansion in bath linen in FY15, TRID is expected to reap its benefits and witness higher utilization (65% in FY20 v/s 50% in FY17), which would not require further addition of spindles as yarn capacity would be utilized in-house.
- ▼ The rising share of copier paper should lead to paper business margin expansion of 340bp to 38% in FY20.
- We value TRID at 11x FY19E EPS, arriving at a TP of INR114. Initiating with Buy.

# Research covered

Cos/Sector	Key Highlights
Trident	An attractive utilization play
India Strategy	Contrarian Investing: Digging deeper; Exploring more angles
P & G Hygiene	P&G Hygiene And Healthcare: Downgrade to Neutral
Castrol India	EBITDA below estimate; lower volumes due to pre-GST destocking




# Piping hot news

# Infosys row: Chorus grows for Seshasayee's exit, Nandan Nilekani's entry

Infosys Ltd chairman R. Seshasayee may be on his way out even as a chorus calling for the return of co-founder Nandan Nilekani grows louder, five days after CEO Vishal Sikka abruptly resigned and the board blamed former chairman and promoter N.R. Narayana Murthy for the exit.

# Chart of the Day: Trident - An attractive utilization play



#### Research

Investors are advised to refer through important disclosures made at the last page of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



# In the news today



Kindly click on textbox for the detailed news link

India's rain deficit widens to 6%, raises crop yield concerns India's rainfall deficit for the June-September monsoon season has widened to 6 percent as of Wednesday, the highest since the season's start on June 1, data compiled by India Meteorological Department (IMD) showed...

## Tatas eye Essar Steel to regain steel crown

Tata Steel, India's second-largest private steelmaker, has expressed interest in bidding for debt-ridden Essar Steel, whose lenders have filed for revival of the company under the Insolvency and Bankruptcy Code, two people with knowledge of the development said. "Tata Steel has informally conveyed to us their interest in bidding for Essar Steel," a senior executive at one of the lenders told ET. An investment banker familiar with the matter said Tata Group's new chairman, N Chandrasekaran, is keen to get back the 'top steelmaker' tag that it lost to JSW Steel...

3

Chinese solar module firms reneging on India contracts India's solar power developers,

# Reliance Industries eyes \$300 million boost from switch to ethane

The ongoing switch to ethane as feedstock at Reliance Industries Ltd's petrochemical units in Dahei, Hazira and Nagothane will drive up operating profit by \$300 million, company executives said... 5

# Tata Power to monetise noncore assets to trim its near Rs 49,000-cr debt

To bring down its around Rs 49,000 crore gross debt, private utility Tata Power is planning to sell its non-core assets even as it continues to explore viable options to resolve issues pertaining to the financially crippled 4,000-megawatts (Mw) Coastal Gujarat Power (CGPL) at Mundra...

# TVS Motor to set up ₹1,110-cr 2-wheeler plant in Mysuru

Karnataka has received an investment proposal from TVS Motor Company to set up a ₹1,100-crore two-wheeler plant in the State. "TVS plans to set up its two-wheeler plant at Bytahalli, Kadakola, in Mysuru...

# Fortis promoters seek SC approval to sell shares pledged with banks, FIs

Fortis promoters Malvinder and Shivinder Singh have approached the Supreme Court (SC) asking for permission to sell their Fortis Healthcare shares already pledged with banks and financial institutions to reduce debt...

24 August 2017





 BSE Sensex
 S&P CNX

 31,292
 9,766

CMP: INR82 TP: INR114 (+39%)

Buy



Stock Info	
Bloomberg	TRID IN
Equity Shares (m)	509.4
52-Week Range (INR)	92/45
M.Cap. (INR b)	41.7
M.Cap. (USD b)	0.7
1, 6, 12 Rel. Per (%)	-3/9/62
Avg Val, (INR m)	129
Free float (%)	32.2

#### Financial Snapshot (INR b)

	•		
Y/E Mar	2017	2018E	2019E
Sales	47.4	52.2	57.1
EBITDA	8.9	9.9	11.1
NP	3.4	4.2	5.3
EPS (INR)	6.6	8.3	10.4
EPS Gr (%)	39.3	25.2	25.5
BV/Sh (INR)	54.1	60.5	68.6
RoE (%)	13.0	14.5	16.1
RoCE (%)	7.5	9.0	10.9
P/E (x)	12.4	9.9	7.9
P/BV (x)	1.5	1.4	1.2

#### Shareholding pattern (%)

As On	Jun-17	Mar-17	Jun-16
Promoter	67.8	67.8	66.5
DII	2.1	2.2	1.6
FII	1.5	1.6	1.0
Others	28.6	28.5	30.9

# Trident An attractive utilization play



Niket Shah +91 22 3980 5436 Niket.Shah@motilaloswal.com

Trident (TRID) is one of India's leading diversified group of businesses headquartered in Ludhiana, Punjab. The company is one of the world's largest manufacturers of integrated home textile (bed and bath linen) and the largest manufacturer of wheat straw-based paper. In FY17, the Home Textile business contributed 82% of its overall revenue, while Paper accounted for 18%. It has manufacturing plants at Budni (MP) and Barnala (Punjab) with combined installed capacity of 115mn kg of yarn, 175k MT of paper, 90MT of bath linen and 43m mtrs of bed linen. TRID also owns the world's largest compact yarn spinning unit under single roof.

# An attractive utilization play

Increasing utilization and entry into bed linen - the key growth drivers

- Home Textile contributes 82% of TRID's revenues. Improving productivity and operating efficiencies are expected to significantly boost utilization in this segment over the coming years (65% utilization in its stronghold bath linen v/s current level of 50%, and 60% utilization in the recently forayed bed linen v/s current level of 29%). The focus on value-added products should help the company improve realization impressively in Home Textile.
- paper accounts for 18% of its revenues. The company has presence in copier paper (~60% of TRID's Paper sales volume), which is among the top-selling brands in India and commands high margins. TRID plans to implement a debottlenecking project to release capacity of 250-275 TPD, improving capacity utilization and allowing further expansion in the copier segment. Increased focus on copier paper is expected to expand TRID's Paper margin by 340bp to 38% in FY20E.
- we estimate a CAGR of 9% in revenue and 24% in PAT over FY17-20, driven by EBITDA margin expansion of 110bp and lower interest expense. We value the stock at 11x FY19E EPS. We initiate coverage with a Buy rating and a target price of INR114, implying 39% upside.

## Margin expansion in Paper business led by copier

Copier paper is among the top selling brands in India and commands high margins. Copier paper contributed 45% of Paper sales volume in FY13, which increased to 60% in FY17. The company intends to leverage strong growth in copier paper in India (CAGR of ~8% v/s ~4% in other paper and stationery) to improve Paper realization and margin (+340bp to 38% in FY20E).


## Enhanced profitability led by bed linen


The company most recently ventured into bed linen, with installed capacity of 43m meters. In the first year of operations, bed linen had 29% utilization, and the company expects to ramp-up operations by adding new clients. TRID has already added more than 10 clients in FY18 so far, including large replenishment clients like IKEA and Amazon. Bed linen currently posts EBITDA loss, which is expected to turnaround by 3QFY18 as utilization reaches 40%. We believe new customer acquisition and the expanding share of TRID in the global textile market should help the bed linen segment increase utilization to 60% in FY20.


24 August 2017



### Stock Performance (1-year)







## Bath linen (towel) inching toward higher utilization

TRID is the market leader in the towel segment in India, and accounts for a significant part (32%) of Indian towel exports to the US. The company used to run at high utilization of 74% in FY13, which declined thereafter as TRID invested heavily in capex and nearly doubled its capacities from 42MT to 90MT to make itself future-ready. Since there would be no further capex, the company expects the plants to return to higher utilization, resulting in margin expansion (as yarn capacity would be utilized in-house and no further spinning capacity would be required). Capacity utilization is expected to reach 65% in FY20E from the current level of 50%.

### Rising share of India in global home textile market

In terry towel category, India accounts for 40% of the global market, which has increased at 15% YoY. India also commands the third largest market share in the Asia-Pacific home textile market, and is expected to grow fastest in the world at a CAGR of 7.2% over 2015-2020. The growing share of India in the global home textile market puts TRID in a sweet spot to garner more market share (evident from the increase in the company's market share in towel exports to the US, from 10% in CY14 to 13% in CY16), particularly in bath linen, where it is the domestic market leader.

## Robust free cash flow generation with major capex cycle behind

In FY16, the company executed greenfield expansion, with total outlay of INR7.5b for 1.9 lac spindles capable of producing compact yarn up to 120 counts. The initiative was taken to attain 100% backward integration for the bed linen unit. The company is not expected to invest heavily in expanding capacities, but is rather likely to improve efficiencies by initiatives such as debottlenecking, which would result in better capacity utilization and thus steady generation of free cash flows in both Paper and Home Textile segments.



### Valuation and view

TRID appears to be at the onset of a high growth cycle, driven by:

- 1. **Growth in bed linen segment:** The company is expected to turn EBITDA profitable in the recently ventured bed linen segment by 3QFY18 as utilization touches 40%. In the first year of operations, bed linen witnessed utilization of 29%, which is expected to increase to 60% in FY20. Also, the segment's share in overall revenue is expected to increase from 4% in FY17 to 9% in FY20.
- 2. Higher utilization in bath linen: TRID used to run at high utilization of 74% in the towel segment in FY13. However, utilization declined thereafter as the company almost doubled its capacity in the segment from 42MT in FY13 to 90MT in FY15 to make itself future-ready. Going forward, the company is expected to witness higher utilization (65% in FY20E v/s 50% in FY17), which would not require further addition of spindles as yarn capacity would be utilized in-house.
- 3. TRID's rising share in global market: The share of Indian companies in the global textile market is on the rise as the country is becoming highly competitive in terms of raw material cost, labor cost and level of automation, leading to improved quality. TRID has been proactive in capitalizing on this opportunity, leading to an increase in the company's share in global towel exports to the US (from 10% in CY14 to 13% in CY16). Also, the company's share in Indian towel exports to the US has also increased from 28% in CY14 to 32% in CY16.
- 4. Paper biz margin driven by branded copier paper: TRID has consistently increased its share of copier paper over the years. Copier paper contributed 45% of the company's overall Paper sales volume in FY13, which increased to 60% in FY17. Since, copier paper commands high margins, we expect Paper business margin to expand 340bp to 38% in FY20.


We believe TRID is set to benefit from multiple factors, including industry growth and expanding share of bed linen/copier paper. Hence, we estimate 9% sales CAGR and 24% PAT CAGR over FY17-20, with improving RoCE and RoE (from 7.5% and 13% in FY17 to 13% and 17.1% in FY20, respectively). IND AS adjustment recognized on fair valuation of PPE to the tune of INR7,582m has resulted in a depressed return ratios, with RoE and RoCE standing at 18.3% and 8.6% in FY17 pre-adjustment v/s 13% and 7.5% in FY17 post-adjustment. Consequently, pre-adjusted RoE and RoCE is expected to increase to 21.4% and 15.1% in FY20E respectively. We value TRID at 11x FY19E EPS, arriving at a TP of INR114, implying 39% upside. We initiate coverage with **Buy**.




# **India Strategy**

BSE Sensex: 31,568 S&P CNX: 9,853

# Please refer our report dated 23 June 2017



## Telecom sector popularity with analysts is very low relative to history



Source: Bloomberg

# **Contrarian Investing: Digging deeper**

## **Exploring more angles**

We interacted with 100+ investors to discuss our recently released thematic report on <u>Contrarian Investing</u>. Interestingly, the discussions have brought to light several fresh angles, which we will explore in this sequel report.

## Price-to-Cash flow theme of Contrarian Investing: Does it work?

In the first version of 'Contrarian Investing,' we explored the theme using relative valuation multiples and dwelt upon P/E and P/B. We concluded that stocks belonging to low P/E quintile have significantly outperformed those from high P/E quintile over the last decade, and that the margin of outperformance is higher on trailing multiples compared to forward multiples. In this report, we will explore if it works the same way for the price-to-cash-flow (P/CF) multiple.

Our analysis reaches a similar conclusion and suggests that, in India, low P/CF stocks outperform high P/CF stocks, and that the margin of outperformance is higher with trailing multiples compared to forward multiples.

### Telecom sector: A review of our framework

The Telecom sector is attracting significant attention, especially after the disruptive entry of RJio. In the previous version, we applied our framework to Metals, IT and Pharma, and concluded that (i) Metals qualified as a Contrarian Investing sector in Mar'16 quarter and (ii) Pharmaceuticals is a sector ripe for Contrarian Investing now. In this sequel, we look at the Telecom sector.

Popularity of the Telecom sector is at a multi-year low, whereas valuation is at an 11% discount to its long-term average EV/EBITDA. The combination of (a) discounted valuations relative to historical averages and (b) low popularity on ratings vis-à-vis history makes Telecom a good contrarian bet, in our view.

## Migration of stocks in Q4: Does it make big difference?

In the previous version, we concluded that Quintile-4 offers the best returns. In most of our subsequent investor meetings on the Contrarian Investing study, we came across questions pertaining to stock migration and stock duration in Q4 (the quintile that delivered the best returns as per our framework). Do stocks stay in Q4 for a reasonable span of time? How many stocks are upgraded from Q5 to Q4, or downgraded from Q3 to Q4? Is return contribution more from members that are upgraded or from those that are part of Q4 for a longer time horizon? In this sequel, we have studied the returns for stocks that are migrating to Q4 from other quintiles. In the 43 quarters covered under our study, we find out that, on average, 11 stocks have remained unchanged from one quarter to another, five are downgraded from Q3 of previous quarter, three are upgraded from Q5 of previous quarter, whereas one member is a new entry from either Q1/Q2 or a new entry in BSE100. Post analyzing returns of these subgroups, we see a marginal difference among members of these groups, though Q4 members from previous quarter have done marginally better.



# Stock positioning: Interesting anomalies

Another interesting angle that we came across relates to the frequency distribution of stocks across quintiles and stock positioning. In the 43 quarters covered under our study, for how many quarters has a stock remained in each quintile and how is it placed currently compared to its most likely position?

Among the Nifty stocks, **Axis Bank**, **SBI**, **BOB**, **NTPC**, **Dr Reddy's**, **Sun Pharma**, **Hindalco**, **IOCL** and **Vedanta** are positioned differently compared to their most likely position.





# P&G Hygiene and Healthcare

BSE SENSEX	S&P CNX
31,568	9,853
Bloomberg	PG IN
Equity Shares (m)	32.5
M.Cap.(INRb)/(USDb)	264.7 /4.1
52-Week Range (INR)	8,390/6,126
1, 6, 12 Rel. Per (%)	3/7/8
Avg Val, INRm/ Vol m	52

29.4

### Financials & Valuations (INR b)

Free float (%)

FY17	FY18E	FY19E
23.2	26.6	31.1
6.6	7.6	8.9
4.3	4.9	5.7
132.9	151.6	176.0
2.3	14.0	16.1
212.2	255.6	306.0
39.3	64.9	62.8
40.2	66.0	63.7
61.3	53.8	46.3
38.4	31.9	26.7
	23.2 6.6 4.3 132.9 2.3 212.2 39.3 40.2 61.3	23.2 26.6 6.6 7.6 4.3 4.9 132.9 151.6 2.3 14.0 212.2 255.6 39.3 64.9 40.2 66.0 61.3 53.8

Estimate change	<b>—</b>
TP change	<b>←→</b>
Rating change	

CMP: INR8,155 TP: INR8,800 (+8%) Downgrade to Neutral

# **GST led destocking impacts sales**

## Downgrading to Neutral on fair near term valuations

- 4QFY17 Net sales (June year-end) declined 5.8% YoY (est. of +7.6%) to INR5b. EBITDA declined by 17.7% YoY (est +2.7%) to INR 1.31b. Adj PAT declined by 28.6% YoY (est. +6%) INR 780m. GST led destocking and higher than expected depreciation and tax rates affected profitability.
- EBITDA margins declined by 380bp YoY to 26.1% in 4QFY17 off a high base as against our expectations of 130bp YoY decline. The operating margin decline was led by gross margins which declined by 390bp YoY to 61.6%. Other expenses increased by 330bp YoY as percentage to sales, while there was 240bp/100bp reduction on staff costs and on A&P.
- Full year FY17 results- Being a June year end company P&GHH witnessed the impact of both demonetization and GST related destocking in a single financial year, unlike peers. The company therefore did a fair job to grow full year sales/EBITDA and PAT at 2%/10% and 2% respectively. Nevertheless weak FY17 base augurs well for recovery going forward.
- Valuation and view: Two factors make PGHH a highly attractive long term core holding (1) Huge category growth potential in the feminine hygiene segment (~70% of sales) and potential for market share growth because of its considerable moats, a combination of which we believe is unsurpassed by other consumer peers and (2) Potentially huge margin gains from premiumization over the longer term in feminine hygiene. With the payout of the huge cash pile, ROCEs have more than doubled and an investor concern has been addressed. Nevertheless near term valuations will look expensive because of the lower other income in FY18/FY19 compared to earlier years. While PGHH remains one of our top long term picks, valuations of 46.3xFY19 EPS do not leave much room for upside over a 1 year horizon leading to downgrade to Neutral.

Standal	one - C	Quarterly	/ Earning	Model
Jeanaai	-	Courter!	Lairing	mouc

Standalone - Quarter	rly Earning	Model									(1	NR Million)
Y/E June		FY1	16			FY17			FY16	FY17	FY17	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Net Sales	5,387	6,593	5,438	5,336	6,004	6,432	5,739	5,029	22,754	23,204	5,739	-12.4%
YoY Change (%)					11.5	-2.4	5.5	-5.8	-2.5	2.0	7.6	
Total Expenditure	4,418	4,431	4,104	3,743	4,493	4,146	4,201	3,718	16,696	16,558	4,108	
EBITDA	970	2,162	1,334	1,593	1,512	2,286	1,538	1,311	6,058	6,646	1,632	-19.6%
Growth					55.9	5.7	15.3	-17.7		9.7	3	
Margins (%)	18.0	32.8	24.5	29.8	25.2	35.5	26.8	26.1	26.6	28.6	28.4	
Depreciation	127	142	124	124	127	132	142	197	517	597	156	
Interest	17	28	7	11	4	43	13	44	63	104	-5	
Other Income	212	206	236	222	225	208	232	108	876	773	62	
PBT	1,038	2,199	1,439	1,680	1,605	2,320	1,614	1,179	6,355	6,718	1,543	-23.6%
Tax	343	733	468	586	561	814	618	398	2,130	2,390	380	
Rate (%)	33.0	33.4	32.5	34.9	34.9	35.1	38.3	33.8	33.5	35.6	24.7	
Adj PAT	696	1,465	971	1,094	1,044	1,506	996	780	4,225	4,327	1,162	-32.9%
YoY Change (%)		61.6	11.7	2.1	50.1	2.8	2.6	-28.6	22.1	2.4	6.4	
Margins (%)	12.9	22.2	17.8	20.5	17.4	23.4	17.4	15.5	18.6	18.6	20.3	

F: MOSI Estimates

24 August 2017





23 August 2017 Results Flash | Sector: Others

Buy

# **Castrol India**

 BSE SENSEX
 S&P CNX

 31,568
 9,853

We will revisit our estimates post earnings call/management interaction.

## **Conference Call Details**



Date: 24<sup>th</sup> August 2017 Time: 2:00 PM IST Dial-in details: +91-22-3938 1094

Financials & Valuations (INR b)

		<u> </u>	
Y/E Dec	2016	2017E	2018E
Net Sales	33.6	36.0	38.5
EBITDA	9.9	10.7	10.9
PAT	6.7	7.1	7.4
EPS (INR)	13.6	14.4	15.0
Gr. (%)	6.3	5.9	4.1
BV/Sh (INR)	12.0	13.5	14.9
RoE (%)	115.2	113.3	106.1
RoCE (%)	115.4	113.5	106.2
P/E (x)	28.5	26.9	25.8
P/BV (x)	32.3	28.9	26.1

CMP: INR389 TP: Under Review

## EBITDA below estimate; lower volumes due to pre-GST destocking

- CSTRL's 2QCY17 revenue declined 10% YoY (+12% QoQ) to INR8.7b (below est. of INR9.4b), driven largely by lower volumes due to impact of GST transition and lingering effect of demonetization.
- n Reported EBITDA of INR2.1b (-33% YoY, -3% QoQ) was significantly below our estimate of INR2.9b, led by an increase in base oil prices due to major supply/demand imbalance in the Asia region.
- **n** EBITDA margin shrunk to 24.1% in 2QCY17 (v/s 29.8% in 1QCY17 and 32.5% in 2QCY16).
- **n** PAT stood at INR1.4b (est. of INR1.9b; -33% YoY, -11% QoQ).
- Management declared an interim dividend of INR4.5/share for CY17; record date is 6 September 2017.
- Lower total volumes: CSTLRL's total volumes were lower due to pre-GST destocking and lingering effect of demonetization. Volume growth was positive for PCMO category (~40% volume share), power brands and industrial segment.
- CSTRL renewed its distribution agreement with Essar Oils for the sale of Castrol lubricants through Essar's retail network.
- The company launched its new product Castrol Hysol XBB in the industrial lubricant segment.

### Valuations and view

20.2

21.4

- n CSTRL's >80% payout policy, RoE/RoCE of ~100% and FCF to PAT conversion at >80% reflect its superior balance sheet and high-quality cash flows, which warrant higher valuation multiples, in our view.
- **n** We will revisit our estimates/target price post the earnings call on 24 August. CSTRL trades at 26.9x/25.8x CY17/CY18E EPS of INR14.4/15. Maintain **Buy**.

(INR Million) **Quarterly Performance** Y/E December **CY16 CY17 1Q** 2Q **3Q 4Q** 2QE YoY (%) 10 2QAct Var (%) QoQ (%) **Net Sales** 8,521 9,679 7.589 7,791 8,822 9,357 8.704 -7% -10% 12% YoY Change (%) 7.1 5.2 -2.8 -1.2 3.5 -3.3 -10.1 **Total Expenditure** 6,005 6,535 5,488 5,627 6,189 6,450 6,609 2% 1% 17% **EBITDA** 2,516 2,101 2,907 2,095 -28% -33% -3% 3,144 2,164 2,633 YoY Change (%) 34.3 15.2 -1.2 3.4 4.7 -7.5 -33.4 29.5 27.7 29.8 Margins (%) 32.5 27.8 31.1 24.1 9% 86 149 107 108 123 143 118 -17% -21% Depreciation 7 -86% Interest 4 1 3 3 4 1 -75% -67% 223 202 183 389 185 212 155 -27% -23% -60% Other Income **PBT** 2,649 3,190 2,176 2,442 2,692 2,972 2,131 -28% -33% -13% 925 778 752 1,121 884 902 1,040 -28% -33% -15% Tax Rate (%) 35 35 36 36 34 35 35 PAT 1,724 2,069 1,398 1,558 1,790 1,932 1,379 -29% -33% -11% YoY Change (%) 48.4 12.1 -2.4 10.7 3.8 -6.6 -33.3

Margins (%)
E: MOSL Estimates

24 August 2017 9

18.4

20.0

20.3

20.6

15.8







# 1. Growth in demand for steel may be around 5%: JSW Steel; Seshagiri Rao, Joint MD & Group CFO

- Internationally steel prices went up further therefore there is a scope for Indian steel prices to go up.
- Considering overall demand situation and outlook, expect steel prices to remain buoyant in international market and domestic steel prices to fluctuate in line with that.
- Generally growth in demand in second half of the year is much better. Hope to see repeat of same thing so growth in demand for steel will be around 5 percent.
- wanted to be a 40 million tonne steel company by 2025. Could be by way of inorganic or organic growth.



# 2. Looking at improvement in operating margin for MEP Biz: Blue Star; Vir Advani, MD

- Have built up MEP business over the last ten years. Have executed over 75 MEP projects in the country.
- **n** Three new projects significant; much larger in value than earlier ones.
- **n** Expect new orders to be completed within 2 years.
- Current order is about Rs 210 crore as of June 30. About 80-85% are MEP projects.
- Looking at improvement in operation margin for MEP business



# 3. Not searching for another partner; focusing on growing business: Max Life; Rajesh Sud, CEO & MD

- Not searching for another partner currently. Focusing on growing business.
- Yes Bank a strong partner for company with regard to bancassurance business.
- **n** Bancassurance is an important channel for company.
- First year premium grew by 19% in Q1.
- Financial savings in India have improved after demonetization and other events. More money coming through formal channels.









# 1. Fixing the trade deficit with china won't be easy

n The ongoing military stand-off with China in the icy Himalayan mountain range has once again brought the issue of trade imbalances with that country to the fore. A bilateral trade deficit should not be a worry in normal circumstances. What really matters is the overall trade balance rather than its individual components. China is quite another matter. Its quest for regional military dominance makes trade imbalances with it a strategic concern for a country such as India. The problem is that the strategic response to this bilateral trade deficit has to go beyond vacuous statements about trade wars or boycotts of Chinese goods. Some soul-searching will also be necessary.



# 2. Creating well-paid jobs for Indians

NITI Aayog has recently issued a set of three documents which give us a fair idea about where national economic policy is headed in the coming years. One of these documents charts out an action agenda for policymakers over the next three years. This article looks past the policy changes that are needed in individual sectors; it focuses on the broader agenda for trade, industry and services outlined by NITI Aayog. The emphasis of the action plan for trade, industry and services is clearly on creating well-paid jobs. NITI Aayog, after making a strong case for export-led re-industrialization, argues, "India needs a focused strategy for creating an environment in which export competitive firms can emerge, especially in labour-intensive sectors.



# 3. The republic of statistical scramble

Indian economy's employment data. One set of numbers claims the current phase of economic growth as jobless. Alternative data sets have accompanied vigorous assertions of rising employment. And then there are many in the middle, trying to make sense of the scant (and outdated) data and wondering how anybody reached any conclusion at all. Welcome to the republic of statistical scramble in the age of Big Data. The Bharatiya Janata Party's (BJP's) 2014 election victory was predicated partly on the promise of enhanced economic well-being; straightening out data inconsistencies should be a priority on the path to fulfilling that promise.



## **International**

# 4. Next fed chair won't really control the fed

n Economists seem increasingly confident that Gary Cohn, the investment banker and White House adviser, will succeed Janet Yellen as head of the Federal Reserve (Fed) when her term ends in February. Whether Cohn or someone else gets the nod, the horse race masks some of the broader dynamics at work in the past decade that have fundamentally altered the Fed, mostly for the better, and continue to shape it in ways once thought inconceivable. The central bank, rightly, gets far more scrutiny from Congress, the media and the public than ever before. That scrutiny stems mainly from the searing 2008-2009 recession and the dramatic steps the Fed took to shore up the financial system and the broader economy. Some public reckoning was bound to result and, properly, seems here to stay.









# Valuation snapshot

		CMP	TP	% Upside		EPS (INF	5)	P/	E (x)	P/	B (x)		ROE (%)	)
Company	Reco	(INR)	(INR)	Downside		FY18E	FY19E	FY17	FY18E		FY18E	FY17		FY19E
Automobiles		()	()	2011110100			/ _							
Amara Raja	Buy	765	986	29	28.0	28.2	37.9	27.3	27.1	5.0	4.4	20.3	17.3	19.9
Ashok Ley.	Buy	103	118	15	4.6	5.2	7.0	22.6	19.9	4.9	4.3	23.1	23.2	27.0
Bajaj Auto	Buy	2,761	3,281	19	132.3	137.2	163.6	20.9	20.1	4.7	4.3	25.3	22.2	24.0
Bharat Forge	Buy	1,168	1,353	16	26.2	36.5	50.5	44.6	32.0	6.6	5.8	16.2	19.2	22.8
Bosch	Neutral	21,841	21,994	1	473.1	547.2	705.7	46.2	39.9	7.6	6.8	15.8	18.0	20.7
CEAT	Buy	1,671	2,029	21	93.3	94.2	126.8	17.9	17.7	2.8	2.5	16.9	14.8	17.3
Eicher Mot.	Buy	30,652	35,854	17	612.7	852.9	1,092.8	50.0	35.9	15.6	11.6	37.1	37.0	35.4
Endurance Tech.	Buy	960	1,059	10	23.5	29.3	37.9	40.9	32.8	7.8	6.5	20.8	21.6	23.3
Escorts	Neutral	613	732	19	20.0	37.1	45.8	30.7	16.5	3.1	2.7	10.6	17.3	18.3
Exide Ind	Buy	199	269	35	8.1	9.2	11.0	24.5	21.6	3.4	3.1	13.9	14.1	15.0
Hero Moto	Neutral	3,890	3,818	-2	169.1	189.3	199.1	23.0	20.5	7.7	6.6	35.7	34.6	31.5
M&M	Buy	1,373	1,618	18	54.3	68.5	82.4	25.3	20.0	3.2	2.9	14.2	13.9	14.9
Mahindra CIE	Not Rated	240	-	10	5.4	9.9	11.8	44.8	24.3	2.8	2.5	6.4	10.8	11.5
Maruti Suzuki	Buy	7,575	8,819	16	248.6	281.7	374.5	30.5	26.9	6.3	5.5	20.3	20.1	22.8
Tata Motors	Buy	380	542	43	19.8	22.4	59.8	19.2	16.9	2.2	2.0	9.8	12.3	26.6
	•		612	43 5	11.7			49.7	40.6		9.5	25.6		33.6
TVS Motor	Buy	584	012	<u>ິ</u>	11./	14.4	23.7		23.8	11.5 <b>4.7</b>	9.5 4.1		25.7	
Aggregate								27.6	23.8	4.7	4.1	17.1	17.4	22.3
Banks - Private	Noutral	EO3	545	0	15 /	21.8	20.1	32.7	23.0	2.2	2.1	6.9	9.3	14.7
Axis Bank	Neutral	503		8	15.4		38.1							
DCB Bank	Neutral	183	192	5	7.0	8.4	10.4	26.2	21.9	2.7	2.2	10.8	11.4	11.8
Equitas Hold.	Buy	158	201	27	5.0	1.7	6.1	31.3	91.1	2.4	2.3	9.5	2.6	8.7
Federal Bank	Buy	107	139	30	4.8	5.4	6.8	22.1	19.8	2.1	1.7	9.9	10.0	10.5
HDFC Bank	Buy	1,773	2,000	13	56.8	68.2	82.1	31.2	26.0	5.3	4.6	18.3	18.8	19.6
ICICI Bank	Buy	298	366	23	15.3	14.9	17.0	19.5	20.0	2.2	2.0	10.2	8.9	9.5
IDFC Bank	Neutral	56	62	11	2.3	2.8	3.2	23.8	20.0	1.3	1.2	5.6	6.3	6.9
IndusInd	Buy	1,661	1,800	8	47.9	61.9	76.8	34.6	26.8	5.0	4.3	15.4	17.3	18.5
J&K Bank	Neutral	81	91	13	-31.3	3.8	8.2	NM	21.0	0.7	0.7	-27.0	3.5	7.2
Kotak Mah. Bk	Buy	980	1,153	18	26.8	32.4	41.0	36.5	30.2	4.7	4.2	13.8	15.0	16.3
RBL Bank	Under Review	510	-		11.9	18.0	23.7	42.9	28.3	4.5	3.2	12.3	13.6	13.9
South Indian	Buy	27	34	25	2.2	2.9	3.7	12.5	9.5	1.1	1.0	9.5	10.8	12.7
Yes Bank	Buy	1,722	2,133	24	73.0	92.3	114.5	23.6	18.7	3.7	3.2	18.9	18.3	19.5
Aggregate								29.3	23.6	3.4	3.0	11.5	12.5	14.2
Banks - PSU														
BOB	Buy	141	198	41	6.0	9.5	20.8	23.5	14.8	0.9	0.9	4.0	6.1	12.4
BOI	Neutral	144	149	4	-14.8	-11.2	6.6	NM	NM	0.6	0.7	-6.7	-5.2	3.0
Canara	Neutral	336	360	7	18.8	30.1	47.0	17.9	11.2	0.7	0.7	4.2	6.2	9.1
IDBI Bk	Neutral	55	49	-10	1.5	6.4	8.6	35.7	8.5	0.5	0.5	1.4	5.8	7.3
Indian Bk	Buy	298	382	28	29.3	34.4	38.3	10.2	8.7	1.0	0.9	10.1	10.9	11.2
OBC	Neutral	123	150	22	-31.6	17.1	21.4	NM	7.2	0.3	0.3	-8.4	4.6	5.4
PNB	Buy	142	184	29	6.2	5.8	11.0	22.9	24.4	8.0	8.0	3.6	3.2	5.9
SBI	Buy	279	341	22	0.3	14.6	26.8	937.1	19.1	1.3	1.2	-0.2	7.0	11.4
Union Bk	Neutral	134	140	4	8.1	9.0	19.1	16.6	14.8	0.4	0.4	2.7	3.0	6.1
Aggregate								99.1	17.6	0.9	0.8	0.9	4.6	8.3
NBFCs														
Bajaj Fin.	Buy	1,779	1,800	1	33.6	47.6	62.9	53.0	37.3	10.1	8.2	21.7	24.3	25.9
Bharat Fin.	Neutral	888	820	-8	21.0	31.8	68.7	42.3	27.9	5.0	4.1	15.1	16.1	28.0
Capital First	Buy	718	925	29	24.6	33.3	44.3	29.1	21.6	3.1	2.7	12.0	13.3	15.6
Cholaman.Inv.&Fn		1,147	1,400	22	46.0	56.0	67.3	25.0	20.5	4.2	3.5	18.0	18.6	19.0
Dewan Hsg.	Buy	468	630	35	29.6	37.7	47.1	15.8	12.4	1.9	1.7	14.4	14.1	15.6
GRUH Fin.	Neutral	503	450	-11	8.1	9.9	12.1	61.8	50.6	18.5	15.2	32.5	33.0	32.8
HDFC	Buy	1,763	1,900	8	46.8	52.9	59.0	37.6	33.3	7.0	6.3	18.9	19.3	18.4
Indiabulls Hsg	Buy	1,217	1,350	11	69.0	86.3	108.4	17.6	14.1	4.2	3.8	25.5	28.2	31.3
L&T Fin Holdings	Buy	173	200	15	5.2	7.3	100.4	33.1	23.7	3.9	3.4	12.4	15.6	19.1
LIC Hsg Fin	Neutral	660	708	7	38.2	41.6	48.9	17.3	15.9	3.1	2.7	19.4	18.2	18.5
-10 1139 1111	Noutiai	000	700	,	JU.Z	71.0	70.7	17.3	10.7	J. I	۷.1	17.4	10.2	10.5



-		CMP	TP	% Upside		EPS (INI	D)	D/I	E (x)	D/	B (x)		ROE (%	<u> </u>
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Manappuram	Not Rated	93	-	DOWNSIGO	8.6	10.8	12.5	10.8	8.6	2.4	2.1	24.0	25.9	26.9
M&M Fin.	Buy	411	459	12	7.1	13.9	17.8	58.0	29.6	3.7	3.4	6.5	12.0	14.2
Muthoot Fin	Buy	445	550	24	29.5	38.2	44.2	15.1	11.6	2.7	2.3	19.4	21.5	21.2
PFC	Neutral	120	117	-3	25.7	27.2	30.2	4.7	4.4	0.8	0.7	17.9	17.0	16.8
Repco Home	Buy	647	800	24	29.1	34.5	39.3	22.2	18.8	3.6	3.0	17.4	17.5	17.0
REC	Neutral	157	134	-15	31.4	35.0	40.4	5.0	4.5	0.9	0.8	19.9	19.1	19.1
Shriram City Union		2,223	2,800	26	84.3	121.7	164.1	26.4	18.3	2.9	2.6	11.7	15.0	17.6
STF	Buy	972	1,330	37	55.6	80.0	102.4	17.5	12.2	2.0	1.7	11.7	15.0	16.9
Aggregate	Day	712	1,000		00.0	00.0	102.1	20.2	16.9	3.4	3.0	16.8	17.6	18.1
Capital Goods								20.2	10.7	0.1	0.0	10.0	17.0	10.1
ABB	Sell	1,354	1,200	-11	19.7	22.4	31.6	68.7	60.4	8.7	7.6	12.7	12.6	15.8
Bharat Elec.	Buy	183	210	15	6.9	7.4	8.3	26.4	24.6	5.4	4.2	20.6	17.0	16.9
BHEL	Sell	128	100	-22	2.1	4.6	4.9	59.4	27.9	1.0	0.9	1.6	3.4	3.5
Blue Star	Neutral	734	650	-11	12.9	17.5	26.1	57.0	41.9	9.3	8.7	18.0	21.4	29.6
CG Cons. Elec.	Buy	214	250	17	4.7	5.0	6.4	45.8	42.6	24.9	18.4	76.4	49.7	49.7
CG Cons. Liec.	Neutral	80	80	0	4.7	2.0	2.5	19.5	39.5	1.2	1.2	6.2	3.0	3.7
Cummins	Buy	881	1,170	33	26.5	27.7	35.0	33.2	31.8	6.5	6.0	21.2	19.7	22.8
GE T&D	Neutral	386	395	2	5.7	9.3	11.3	67.4	41.6	9.6	8.4	12.4	21.5	22.8
Havells	Neutral	477	455	-5	9.6	10.9	13.8	49.8	43.6	9.0	8.1	18.2	18.6	20.7
K E C Intl	Neutral	299	295	-5 -1	11.9	13.1	16.4	25.2	22.9	4.8	4.1	21.2	19.5	20.7
					42.3	44.8	51.7		25.1	3.1	2.9	12.2	19.5	12.9
L&T	Buy Not Dated	1,124	1,345	20				26.6						
Pennar Eng.	Not Rated	95	- 1 255	0	7.1	9.1	11.2	13.5	10.5	1.4	1.2	10.2	11.6	12.6
Siemens	Neutral	1,257	1,355	8	17.8	22.7	33.0	70.5	55.4	6.6	5.7	9.3	10.3	13.7
Solar Ind	Neutral	859	900	5	20.6	24.2	30.0	41.7	35.5	7.6	6.5	19.8	19.8	20.9
Suzlon Energy	Not Rated	16	-		0.6	0.9	1.0	25.9	18.6	-1.5	-1.6	NM	-8.8	-11.0
Thermax	Neutral	872	830	-5	30.8	30.0	33.2	28.3	29.1	3.9	3.5	14.3	12.7	12.8
Va Tech Wab.	Buy	605	800	32	29.8	34.6	39.8	20.3	17.5	3.3	2.9	16.8	17.6	17.4
Voltas	Sell	522	430	-18	15.5	16.8	19.1	33.7	31.1	5.2	4.6	18.0	15.8	16.0
Aggregate								34.0	30.0	3.8	3.5	11.2	11.6	12.6
Cement														
Ambuja Cem.	Buy	276	308	12	4.9	7.0	8.2	56.5	39.7	2.9	2.7	5.1	7.0	7.9
ACC	Neutral	1,803	1,622	-10	36.1	49.8	65.0	49.9	36.2	3.9	3.8	7.9	10.6	13.1
Birla Corp.	Buy	954	1,150	21	29.4	40.9	58.9	32.5	23.3	2.2	2.1	7.3	9.2	12.2
Dalmia Bharat	Buy	2,592	3,282	27	38.8	68.7	89.9	66.9	37.8	4.6	4.2	7.2	11.6	13.4
Grasim Inds.	Neutral	1,119	1,079	-4	67.9	71.3	102.7	16.5	15.7	1.8	1.6	11.5	10.9	13.9
India Cem	Neutral	178	201	13	5.6	8.0	11.8	31.7	22.3	1.1	1.0	3.4	4.7	6.6
J K Cements	Buy	1,013	1,277	26	33.7	39.7	54.4	30.0	25.5	4.0	3.5	14.4	14.8	17.5
JK Lakshmi Ce	Buy	416	519	25	7.0	9.7	16.4	59.7	42.7	3.5	3.2	6.0	7.9	12.1
Ramco Cem	Buy	666	806	21	27.3	27.4	34.4	24.4	24.3	4.2	3.7	19.0	16.1	17.5
Orient Cem	Buy	151	185	23	-1.6	4.4	7.1	NM	34.1	3.1	2.9	-3.2	8.8	12.8
Prism Cem	Buy	111	140	26	0.3	3.5	5.6	406.1	31.8	5.8	5.1	1.4	17.0	22.9
Shree Cem	Buy	17,183	22,360	30	384.4	460.4	547.8	44.7	37.3	7.8	6.5	18.4	19.1	19.1
Ultratech	Buy	3,964	4,936	25	96.1	91.5	138.8	41.3	43.3	4.5	4.2	11.6	10.1	14.0
Aggregate								36.2	31.1	3.5	3.2	9.6	10.3	12.7
Consumer														
Asian Paints	Neutral	1,140	1,200	5	21.0	22.2	26.5	54.2	51.4	14.4	13.1	28.5	26.7	28.1
Britannia	Buy	4,251	4,660	10	73.7	85.3	104.6	57.7	49.8	18.9	15.6	36.9	34.3	34.5
Colgate	Buy	1,086	1,285	18	21.2	24.4	29.8	51.2	44.4	23.2	22.0	50.4	50.8	58.2
Dabur	Neutral	299	315	6	7.2	7.7	9.1	41.2	38.6	10.8	9.3	28.4	26.0	26.3
Emami	Buy	1,085	1,310	21	26.5	26.9	33.1	40.9	40.3	14.0	12.0	35.8	32.0	33.9
Godrej Cons.	Neutral	905	995	10	18.9	21.5	24.7	47.9	42.0	11.6	9.0	24.6	24.2	22.8
GSK Cons.	Sell	5,346	4,500	-16	156.1	158.1	182.1	34.2	33.8	7.2	7.1	22.2	21.1	22.6
HUL	Buy	1,188	1,360	15	19.6	22.9	27.3	60.5	51.8	38.6	37.2	65.6	73.1	82.8
ITC	Neutral	282	280	-1	8.4	9.3	10.3	33.6	30.4	7.6	7.5	23.5	24.8	26.3
Jyothy Lab	Neutral	372	395	6	11.2	9.8	11.1	33.1	37.9	6.2	6.3	21.1	16.5	18.4



Company         Reco         (INR)         (INR)         Downside         FY17         FY18E         FY19E         FY17         FY18E         FY18E         FY18E         FY17         FY18E         FY18E<			CMP	TP	% Upside		EPS (INF	R)	P/F	E (x)	P/F	3 (x)		ROE (%)	)
Nestle Sell 6,625 5,740 .13 1180 151, 1336 561, 57.6 21 2 17, 390, 355 381 381 agreen from the proper from the	Company	Reco			•			•							
Page Infols   Buy	Marico	Neutral	316	355	12	6.3	6.8	8.2	50.2	46.3	17.5	15.0	36.7	34.9	37.7
Paragnamik   Neutral   239   245   3   3.6   9.1   125   6.02   26.2   31.   2.7   5.0   0.1   10.   13.5   10.     Parabhat Dari Neutral   315   810   11.   14.7   15.8   18.1   20.6   43.7   43.1   20.8   22.2   23.5     Parabhat Dari Not Rated   132   -	Nestle	Sell	6,625	5,740	-13	118.0	115.1	133.6	56.1	57.6	21.2	19.7	39.0	35.5	38.1
PRIMIER IN   Noutral   815   810   -1   16,7   811   20,6   487   45.1   12,6   10,3   82,2   25,2   23,5     Prabhat Dairy   Not Rated   132   -1   34,9   15,5   81,0   37,5   38,0   19   13,8   52,9   74,0     Prabhat Dairy   Not Rated   132   -1   3,5   35   54   47,5   38,0   19   13,8   52,4   47,8     Nottral   24,72   2,525   2   26,7   31,5   51,5   31,0   19,0   13,8   52,0   29,3     Magnegate   Heathbare   Hea	Page Inds	Buy	17,214	19,600	14	238.7	294.7	398.4	72.1	58.4	28.8	23.1	40.0	39.6	43.1
PRAG-Phyginer   Neutral   1,155   8,200   11   144.9   155.8   181.6   50.3   52.3   46.5   37.1   45.3   78.9   74.0	Parag Milk	-		245	3	3.6	9.1	12.5	66.2	26.2	3.1	2.7	6.0	11.0	13.3
PRAG-Phyginer   Neutral   1,155   8,200   11   144.9   155.8   181.6   50.3   52.3   46.5   37.1   45.3   78.9   74.0	Pidilite Ind.	Neutral	815	810	-1	16.7	18.1	20.6	48.7	45.1	12.6	10.3	28.2	25.2	23.5
Prabhat Dalpy Nor Rated   132     35   35   36   37   38   30   19   18   52   49   8.5   United Erem Neutral   2,472   2,525   2   26.7   34.5   51.5   92.4   71.6   18.5   12.9   21.3   18.0   20.3	P&G Hygiene			8,800	11	144.9	155.8	181.6	56.3	52.3	46.5	37.1	45.3		
United Spirits   Neutral   2,472   2,525   2   26,7   31,5   51,5   92,4   71,6   18,5   12,9   21,3   18,0   20,3     Aggregate		Not Rated		-		3.5	3.5	6.4	37.5	38.0	1.9	1.8	5.2	4.9	8.5
	United Brew			875	9	8.7						8.4			
Healthcare   Hea					2										
	· ·		•												
Alkem Laba  Alkem Laba  Alkem Laba  Alkem Laba  Alkem Laba  Algent Pahram  Buy  1.191  1.606  305  508  508  509  303  309  000  10000  10000  10000  10000  10000  10000  10000  10000  10000  10000  10000  10000  10000  10	Healthcare														
Ajanta Pharma   Buy	Alembic Phar	Neutral	506	510	1	21.6	20.5	25.5	23.4	24.7	5.0	4.4	23.0	19.0	20.4
Ajanta Pharma   Buy	Alkem Lab				2										
Aurobindo Buy 699 850 22 39.3 44.9 50.0 17.8 15.6 4.4 3.5 27.6 24.8 22.1 Blocon Sell 330 330 0 10.2 27.7 14.2 32.4 34.0 4.1 3.8 12.3 11.1 12.0 12.0 12.0 12.0 12.0 12.0 12.0															
Blocon	•	-													
Cadilia         Buy         463         555         20         14.2         17.9         24.1         32.6         25.8         6.8         5.7         23.0         23.9         26.3           Cipla         Neutral         560         520         -7         15.9         21.1         62.0         35.2         25.5         3.6         3.2         23.0         12.1         13.2           Divisitab         Neutral         639         680         6         39.7         33.6         40.0         16.1         19.0         3.6         3.3         23.5         18.1         14.9           Gentales         Neutral         601         77.5         29         39.3         42.9         51.7         15.6         32.2         21.1         17.7         18.8           Genules         Buy         128         200         56         7.2         82.2         11.5         17.7         15.6         32.2         22.1         11.1         17.7         18.8           GENK Pharma         Neutral         411         430         5         16.1         16.6         26.8         25.0         24.8         21.2         20.8         8.2         12.2		-													
Cipla         Neutral         560         520         -7         15.9         21.1         26.0         35.2         26.5         3.6         3.2         10.2         12.1         13.2           Divis Lab         Neutral         639         680         6         39.7         33.6         40.0         16.1         19.0         3.6         3.3         23.5         18.1         19.4           FOR Reddys         Neutral         2,030         25.00         23         72.6         85.1         125.2         28.0         23.8         2.7         26         9.6         11.3         14.8           FOR Health         Buy         153         220         44         10.3         2.2         5.6         14.7         69.9         1.6         1.4         11.3         21.4         4.9           Glenmark         Neutral         411         430         5.0         7.2         82.2         11.5         17.7         15.6         3.3         2.0         2.2         21.1         17.7         15.6         3.3         2.2         2.0         11.7         14.5         2.0         8.8         8.2         12.2           Jubliant Life         Buy         719															
Divis Lab   Neutral   639   680   6   39.7   33.6   40.0   16.1   19.0   3.6   3.3   23.5   18.1   19.4		•													
Dr Reddy's   Neutral   2,030   2,500   23   72.6   85.1   125.2   28.0   23.8   2.7   2.6   9.6   11.3   14.8     Fortis Health   Buy   153   220   44   10.3   2.2   5.6   14.7   6.9   1.6   1.4   11.3   2.1   4.9     Gelemark   Neutral   601   775   29   39.3   42.9   51.7   15.3   14.0   3.8   3.0   24.2   21.6   2.0     Granules   Buy   128   200   56   7.2   8.2   11.5   17.7   15.6   3.2   2.2   21.1   17.7   18.8     GSK Pharma   Neutral   411   430   5   61.1   16.6   26.8   25.6   24.8   2.1   2.0   8.6   8.2   2.2     Jubilant Life   Buy   719   905   26   37.0   47.1   56.7   19.5   15.3   3.3   2.7   18.1   19.5   19.6     Lupin   Buy   3.993   4.820   21   129.1   13.6   16.0   3.8   3.0   24.7   18.1   19.5   19.6     Sanofi India   Buy   3.993   4.820   21   129.1   13.6   16.0   3.8   3.0   2.7   10.7   14.4   17.0   20.4     Strides Shasun   Buy   409   515   1.0   26.1   14.0   21.1   30.4   39.6   26.2   4.8   4.1   14.4   17.0   20.4     Strides Shasun   Buy   409   515   10   26.1   15.1   30.4   39.6   26.2   4.8   4.1   14.4   17.0   20.4     Strides Shasun   Buy   409   515   10   26.1   15.1   18.0   33.7   27.6   8.5   6.2   2.2   2.5   20.7     Torrort Pharma   Noutral   1,208   1,350   12   55.2   53.4   67.3   21.9   22.6   4.7   4.1   23.8   19.5   21.5     Aggregate   Torrort Pharma   Noutral   1,208   1,214   4.7   3.8   4.9   4.1   4.8   4.1   4.7   4.8   4.9   4.8   4.1   4.8   4.1   4.8   4.9   4.8   4.1   4.8   4.1   4.8   4.1   4.8   4.1   4.8   4.8   4.1   4.8   4.8   4.1   4.8   4.8   4.1   4.8   4.8   4.1   4.8   4.8   4.1   4.8															
Fortis Health Buy 153 220 44 10.3 2.2 5.6 14.7 69.9 16.0 14.0 14.0 13.0 14.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 14.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 14.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15															
Glenmark Noutral 601 775 29 39.3 42.9 51.7 15.3 14.0 3.8 3.0 24.7 21.6 29.9 Granules Buy 128 200 56 7.2 8.2 11.5 17.7 15.6 3.2 22 21.1 17.7 18.8 56.5 April 18.9 19.9 19.0 19.0 19.0 19.0 11.7 14.5 23.0 30.9 IPCA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 2.1 2.0 8.6 23.0 30.9 IPCA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 2.1 2.0 8.6 23.0 30.9 IPCA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 2.1 2.0 8.6 23.0 30.9 IPCA Labs Neutral 411 430 5 16.0 37.0 47.1 56.7 19.5 15.3 3.3 2.7 18.1 19.5 19.6 Lupin Buy 955 1,125 18 55.8 41.4 56.3 17.1 23.1 3.2 2.9 20.6 13.2 16.0 Sanofi India Buy 3.993 4.820 21 12.91 133.6 160.6 30.9 29.9 5.3 4.9 17.1 16.6 18.1 Shilpa Medicare Buy 554 805 45 14.0 21.1 30.4 39.6 26.2 4.8 4.1 14.4 17.0 20.4 Strides Shasun Buy 915 1,300 42 32.3 47.4 74.8 28.4 19.3 30. 27 10.7 14.7 20.2 Sun Pharma Buy 469 515 10 26.1 15.1 23.3 17.9 31.1 3.1 3.1 18.5 10.0 14.7 Syngene Intl Not Rated 439 - 13.0 12.5 52 53.4 67.3 21.9 22.6 4.7 4.1 23.8 19.5 21.5 Torrent Pharma Neutral 1,208 1,350 12 55.2 53.4 67.3 21.9 22.6 4.7 4.1 23.8 19.5 21.5 Aggregate 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.															
Granules Buy 128 200 56 7.2 8.2 11.5 17.7 15.6 3.2 2.2 21.1 17.7 18.8 CSK Pharma Neutral 2,381 2,500 5 34.4 46.8 54.9 69.3 50.9 10.0 11.7 14.5 23.0 30.9 PICA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 21. 2.0 10.1 17.7 18.5 23.0 30.9 PICA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 21.1 2.0 10.1 17.7 18.5 23.0 30.9 PICA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 21.1 2.0 10.1 17.7 18.5 23.0 30.9 PICA Labs Neutral 411 430 5 16.1 16.6 26.8 25.6 24.8 21.1 2.0 18.0 15.7 19.6 19.6 19.0 19.0 19.0 19.0 19.0 19.0 19.0 19.0		-													
GSK Pharma         Neutral         2,381         2,500         5         34.4         46.8         54.9         69.3         50.9         10.0         11.7         14.5         23.0         30.9           IPCA Labs         Neutral         411         430         5         16.1         16.6         26.8         25.6         24.8         2.1         2.0         8.6         8.2         12.2           Jubilant Life         Buy         719         905         26         37.0         47.1         56.7         19.5         15.3         3.2         2.9         8.0         19.6         19.5           Lupin         Buy         3,993         4,820         21         129.1         13.0         16.0         30.9         29.9         5.3         4.9         17.1         16.0         18.1           Shilpa Medicare         Buy         554         805         45         14.0         21.1         30.4         30.6         26.2         4.8         4.1         14.7         70.0         26.2           Strides Shasun         Buy         469         515         10         26.1         51.2         30.3         17.9         26.6         4.2         21.0 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>															
PCA Labs   Neutral   411   430   5   16.1   16.6   26.8   25.6   24.8   2.1   2.0   8.6   8.2   12.2   Jubilant Life   Buy   779   905   26   37.0   47.1   56.7   19.5   15.3   3.3   2.7   18.1   19.5   19.6   Lupin   Buy   955   1,125   18   55.8   41.4   56.3   17.1   23.1   3.2   2.9   20.6   13.2   16.0   Sanofi India   Buy   3,993   4,820   21   12.91   133.6   160.6   30.9   29.9   5.3   4.9   17.1   16.6   18.1   Shilpa Medicare   Buy   554   805   45   14.0   21.1   30.4   39.6   26.2   4.8   4.1   14.4   17.0   20.4   Strides Shasun   Buy   915   1,300   42   32.3   47.4   74.8   28.4   19.3   3.0   2.7   10.7   14.7   20.2   Stun Pharma   Buy   469   515   10   26.1   15.1   23.3   17.9   22.5   24.8   3.1   3.1   18.5   10.0   14.7   Syngene Int   Not Rated   449   - 13.0   16.1   18.0   33.7   27.2   6.8   56.6   22.2   22.5   20.7   Torrent Pharma   Neutral   1,208   1,350   12   55.2   53.4   67.3   21.9   22.6   4.7   4.1   23.8   19.5   21.5   23.2		•													
Designate   Designation   Design															
Lupin         Buy         955         1,125         18         55.8         41.4         56.3         17.1         23.1         3.2         2.9         20.6         13.2         16.0           Sanofi India         Buy         3,993         4,820         21         129.1         133.6         160.6         30.9         29.9         5.3         4.9         17.1         16.6         18.1           Shrilpa Medicare         Buy         554         805         45         14.0         21.1         30.4         39.6         26.2         48         4.1         14.4         17.0         20.2           Strides Shasun         Buy         469         515         10         26.1         15.1         23.3         17.9         31.1         3.1         18.5         10.0         14.7           Syngene Intl         Not Rated         439         -         13.0         16.1         18.0         33.7         27.2         6.8         5.6         22.2         22.5         20.7           Torrent Pharm         Neutral         1,208         1,350         12         55.2         53.4         67.3         21.9         22.6         4.7         4.1         23.8         19.5 <td></td>															
Sanofi India         Buy         3,993         4,820         21         129.1         133.6         160.6         30.9         29.9         5.3         4.9         17.1         16.6         18.1           Shilpa Medicare         Buy         554         805         45         14.0         21.1         30.4         39.6         26.2         4.8         4.1         14.4         17.0         20.4           Strides Shasun         Buy         469         515         10         26.1         15.1         23.3         17.9         31.1         3.1         18.5         10.0         14.7           Syngene Int         Not Rated         439         -         13.0         16.1         18.0         33.7         27.2         6.8         5.6         22.2         22.5         20.7           Torrent Pharma         Neutral         1,208         1,350         12         55.2         53.4         67.3         21.9         22.6         4.7         4.1         23.8         19.5         21.5           Aggregate         -         -         102.5         12.9         9.8         11.2         13.3         16.7         14.6         2.5         2.2         12.6         16.0 </td <td></td> <td>-</td> <td></td>		-													
Shilpa Medicare         Buy         554         805         45         14.0         21.1         30.4         39.6         26.2         4.8         4.1         14.4         17.0         20.4           Strides Shasun         Buy         915         1,300         42         32.3         47.4         74.8         28.4         19.3         3.0         2.7         10.7         14.7         20.2           Sun Pharma         Buy         469         515         10         26.1         15.1         23.3         17.9         31.1         3.1         18.5         10.0         14.7           Syngene Inth         Not Rated         439         -         13.0         16.1         18.0         33.7         27.2         6.8         6.6         22.2         22.5         20.7           Torrent Pharma         Neutral         1,208         1,350         12         25.2         24.6         4.7         4.1         23.8         19.5         21.5           Aggregate		-													
Strides Shasun         Buy         915         1,300         42         32.3         47.4         74.8         28.4         19.3         3.0         2.7         10.7         14.7         20.2           Sun Pharma         Buy         469         515         10         26.1         15.1         23.3         17.9         31.1         3.1         3.1         18.5         10.0         14.7           Syngene Inth         Not Rated         439         -         13.0         16.1         18.0         33.7         27.2         6.8         5.6         22.2         22.5         20.7           Aggregate               164         212         29         9.8         11.2         13.3         16.7         14.6         2.5         2.2         12.6         16.0         16.8           Blue Dart         Not Rated         4,116         -         102.5         12.9         163.2         40.1         31.7         17.8         13.6         50.5         48.6         48.6           Gateway         Buy         230         272         18         6.8         9.0         12.4         33.8 <td< td=""><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>		-													
Sun Pharma         Buy         469         515         10         26.1         15.1         23.3         17.9         31.1         3.1         3.1         18.5         10.0         14.7           Syngene Intl         Not Rated         439         -         13.0         16.1         18.0         33.7         27.2         6.8         5.6         22.2         22.5         20.7           Torrent Pharma         Neutral         1,208         1,350         12         55.2         53.4         67.3         21.9         22.6         4.7         4.1         23.8         19.5         21.5           Aggregate         2         2.2         24.2         3.7         3.4         16.9         16.3           Blue Dart         Not Rated         4,116         -         102.5         129.9         163.2         40.1         31.7         17.8         13.6         50.5         48.6         46.8           Concor         Neutral         1,262         1,214         -4         38.0         42.1         48.6         33.2         30.0         3.5         3.3         10.8         16.9         21.0         25.9         16.1         31.0         13.6         7.2         12.9 <td></td>															
Syngene Inth         Not Rated         439         -         13.0         16.1         18.0         33.7         27.2         6.8         5.6         22.2         22.5         20.7           Torrent Pharma         Neutral         1,208         1,350         12         55.2         53.4         67.3         21.9         22.6         4.7         4.1         23.8         19.5         21.5           Aggregate         22.1         24.2         37.         34         16.9         14.1         16.3           Logistics         Buy         164         212         29         9.8         11.2         13.3         16.1         14.6         2.5         2.2         12.6         16.0         16.8           Blue Dart         Not Rated         4,116         -         102.5         12.99         163.2         40.1         31.7         17.8         13.6         50.5         48.6         46.8           Concor         Neutral         1,262         1,214         4         38.0         42.1         48.6         33.2         30.0         3.5         3.3         10.8         11.2         4         4         4         38.0         42.1         48.6         33.2		-													
Torrent Pharma   Neutral   1,208   1,350   12   55.2   53.4   67.3   21.9   22.6   4.7   4.1   23.8   19.5   21.5     Aggregate   22.1   24.2   3.7   3.4   16.9   14.1   16.3     Logistics   Suy   164   212   29   9.8   11.2   13.3   16.7   14.6   2.5   2.2   12.6   16.0   16.8     Blue Dart   Not Rated   4,116   -   102.5   12.9   16.2   42.1   48.6   33.2   30.0   3.5   3.3   10.8   10.3   12.4     Gateway Distriparks   Buy   230   272   18   6.8   4.8   15.9   23.9   13.6   7.2   1.9   1.7   12.4   19.4   25.4     Transport Corp.   Not Rated   114   -   8.4   15.9   23.9   13.6   7.2   1.9   1.7   12.4   19.4   25.4     Transport Corp.   Not Rated   273   -   16.9   21.0   25.9   16.1   13.0   2.5   2.1   16.7   17.8   18.6     Aggregate   273   373   450   21.0   21.0   25.9   16.1   31.0   2.5   21.1   16.7   17.8   18.6     Aggregate   284   294   294   294   294   294   294   294   294   294   294   294     Dish TV   Buy   80   106   32   10.0   13.3   4.3   81.1   61.2   17.4   13.5   24.1   24.9   99.2     Dis Corp   Buy   371   450   21   20.4   23.7   27.6   18.2   15.6   4.3   3.8   25.5   25.8   26.6     Den Net.   Neutral   91   90   -1   -8.6   -2.7   0.3   NM   NM   1.7   1.8   -12.0   -5.3   0.7     Ent. Network   Neutral   815   928   14   11.4   13.4   21.7   71.3   61.0   4.5   4.2   6.7   7.2   10.7     Hind. Media   Buy   267   350   31   25.9   28.3   33.6   10.3   9.4   18.   1.5   19.0   17.3   17.3     HT Media   Neutral   91   90   -2   7.4   7.9   8.1   12.3   11.5   0.8   0.8   7.1   6.9   6.4     Augis Broadcast   Buy   372   469   26   6.4   9.3   14.4   15.0   57.9   3.9   3.9   3.5   3.5   10.4   14.0   18.2     Every   Siti Net.   Neutral   25   32   30   -1.8   0.3   0.4   NM   NM   NM   3.4   3.6   -2.5   5.4   14.1   14.0   18.2     Every   Siti Net.   Neutral   25   32   30   -1.8   0.3   0.4   NM   NM   NM   3.4   3.6   -2.5   5.4   4.1   14.0   18.2     Every   Siti Net.   Neutral   25   32   30   -1.8   0.3   0.4   NM   NM   NM   3.4   3.6   -2.5   5.4   4.1   1.6   1.		•			10										
Magnegate					12										
Milcargo Logistics		Neutrai	1,200	1,330	12	55.2	33.4	07.3							
Alicargo Logistics Buy 164 212 29 9.8 11.2 13.3 16.7 14.6 2.5 2.2 12.6 16.0 16.8 Blue Dart Not Rated 4,116 - 102.5 129.9 163.2 40.1 31.7 17.8 13.6 50.5 48.6 46.8 Concor Neutral 1,262 1,214 -4 38.0 42.1 48.6 33.2 30.0 3.5 3.3 10.8 11.3 12.4 Gateway Distriparks Buy 230 272 18 6.8 9.0 12.4 33.8 25.5 2.5 2.5 2.3 7.3 9.4 12.4 Satisfy Distriparks Distriparks Day 230 272 18 6.8 9.0 12.4 33.8 25.5 25. 2.5 2.3 7.3 9.4 12.4 Satisfy Distriparks Day 230 272 18 6.8 9.0 12.4 33.8 25.5 25. 25. 2.3 7.3 9.4 12.4 Satisfy Distriparks Day 230 272 18 6.8 9.0 12.4 33.8 25.5 25. 25. 2.3 7.3 9.4 12.4 Satisfy Distriparks Day 230 272 18 6.8 9.0 12.4 33.8 25.5 25. 25. 25. 25. 10.7 1.7 12.4 19.4 25.4 Satisfy Distriparks Day 27.0 16.9 21.0 25.9 16.1 13.0 2.5 2.1 16.7 17.8 18.6 Satisfy Day 28.0 10.6 32 1.0 1.3 4.3 81.1 61.2 17.4 13.5 24.1 13.8 15.4 Satisfy Day 28.0 10.6 32 1.0 1.3 4.3 81.1 61.2 17.4 13.5 24.1 24.9 99.2 DB Corp Buy 371 450 21 20.4 23.7 27.6 18.2 15.6 4.3 3.8 25.5 25.8 26.6 Den Net Neutral 91 90 -1 8.6 -2.7 0.3 NM NM NM 1.7 1.8 -12.0 -5.3 0.7 Ent.Network Neutral 815 928 14 11.4 13.4 21.7 71.3 61.0 4.5 4.2 6.7 7.2 10.7 Hind. Media Buy 267 350 31 25.9 28.3 33.6 10.3 9.4 1.8 1.5 19.0 17.3 17.3 HT Media Neutral 91 90 -2 7.4 7.9 8.1 12.3 11.5 0.8 0.8 7.1 6.9 6.4 Jagran Prak. Buy 175 225 28 10.8 12.4 14.1 16.3 14.2 2.4 2.3 17.6 16.5 17.4 Music Broadcast Buy 372 469 26 6.4 9.3 14.0 57.9 39.9 3.9 3.5 11.2 9.3 12.4 PVR Buy 1,259 1,628 29 20.5 30.9 46.9 61.3 40.8 6.1 5.3 10.4 14.0 18.2 Siti Net. Neutral 25 32 30 -1.8 -0.3 0.4 NM NM NM NM 3.4 3.6 -23.5 -4.1 6.2 Siti Net.									22.1	24.2	3.1	3.4	10.9	14.1	10.3
Blue Dart   Not Rated   4,116   -   102.5   129.9   163.2   40.1   31.7   17.8   13.6   50.5   48.6   46.8     Concor   Neutral   1,262   1,214   -4   38.0   42.1   48.6   33.2   30.0   3.5   3.3   10.8   11.3   12.4     Gateway Distriparks   Buy   230   272   18   6.8   9.0   12.4   33.8   25.5   2.5   2.3   7.3   9.4   12.4     Gati   Not Rated   114   -     8.4   15.9   23.9   13.6   7.2   1.9   1.7   12.4   19.4   25.4     Transport Corp.   Not Rated   273   -   16.9   21.0   25.9   16.1   13.0   2.5   2.1   16.7   17.8   18.6     Aggregate		Dina	141	212	20	0.0	11 2	12.2	14 7	114	2.5	2.2	12.4	14.0	14 0
Concor         Neutral         1,262         1,214         -4         38.0         42.1         48.6         33.2         30.0         3.5         3.3         10.8         11.3         12.4           Gateway Distriparks         Buy         230         272         18         6.8         9.0         12.4         33.8         25.5         2.5         2.3         7.3         9.4         12.4           Gati         Not Rated         114         -         8.4         15.9         23.9         13.6         7.2         1.9         1.7         12.4         19.4         25.4           Transport Corp.         Not Rated         273         -         16.9         21.0         25.9         16.1         13.0         2.5         2.1         16.7         17.8         18.6           Aggregate         -         16.9         21.0         25.9         16.1         13.0         2.5         2.1         16.7         17.8         18.6           Aggregate         -         29.7         24.9         3.7         3.4         12.4         13.8         15.4           Media         Buy         80         106         32         1.0         1.3         4.3		-			29										
Gateway Distriparks         Buy         230         272         18         6.8         9.0         12.4         33.8         25.5         2.5         2.3         7.3         9.4         12.4           Gati         Not Rated         114         -         8.4         15.9         23.9         13.6         7.2         1.9         1.7         12.4         19.4         25.4           Transport Corp.         Not Rated         273         -         16.9         21.0         25.9         16.1         13.0         2.5         2.1         16.7         17.8         18.6           Aggregate         -         29.7         24.9         3.7         3.4         12.4         13.8         15.4           Media         -         -         10.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           Dish TV         Buy         80         106         32         1.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           De Scorp         Buy         371         450         21         20.4         23.7 <t< td=""><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>					1										
Distriparks         Buy         230         272         18         6.8         9.0         12.4         33.8         25.5         2.5         2.3         7.3         9.4         12.4           Gati         Not Rated         114         -         8.4         15.9         23.9         13.6         7.2         1.9         1.7         12.4         19.4         25.4           Transport Corp.         Not Rated         273         -         16.9         21.0         25.9         16.1         13.0         2.5         2.1         16.7         17.8         18.6           Aggregate         29.7         24.9         3.7         3.4         12.4         13.8         15.4           Media           Dish TV         Buy         80         106         32         1.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           De Corp         Buy         371         450         21         20.4         23.7         27.6         18.2         15.6         4.3         3.8         25.5         25.8         26.6           Den Net.         Neutral		Neutrai	1,202	1,214	-4	30.0	42.1	40.0	33.2	30.0	3.3	3.3	10.0	11.3	12.4
Gati         Not Rated         114         -         8.4         15.9         23.9         13.6         7.2         1.9         1.7         12.4         19.4         25.4           Transport Corp.         Not Rated         273         -         16.9         21.0         25.9         16.1         13.0         2.5         2.1         16.7         17.8         18.6           Aggregate         29.7         24.9         3.7         3.4         12.4         13.8         15.4           Media           Dish TV         Buy         80         106         32         1.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           De Corp         Buy         371         450         21         20.4         23.7         27.6         18.2         15.6         4.3         3.8         25.5         25.8         26.6           Den Net.         Neutral         91         90         -1         -8.6         -2.7         0.3         NM         NM         1.7         1.8         -12.0         -5.3         0.7           Ent. Network         Neutral         815	•	Buy	230	272	18	6.8	9.0	12.4	33.8	25.5	2.5	2.3	7.3	9.4	12.4
Transport Corp.         Not Rated         273         -         16.9         21.0         25.9         16.1         13.0         2.5         2.1         16.7         17.8         18.6           Aggregate         29.7         24.9         3.7         3.4         12.4         13.8         15.4           Media           Dish TV         Buy         80         106         32         1.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           D B Corp         Buy         371         450         21         20.4         23.7         27.6         18.2         15.6         4.3         3.8         25.5         25.8         26.6           Den Net.         Neutral         91         90         -1         -8.6         -2.7         0.3         NM         NM         1.7         1.8         -12.0         -5.3         0.7           Ent. Network         Neutral         815         928         14         11.4         13.4         21.7         71.3         61.0         4.5         4.2         6.7         7.2         10.7           Hind. Media         Buy		Not Rated	114			8.4	15 9	23.9	13.6	7.2	1 9	1 7	12 4	19 4	25.4
Aggregate         29.7 24.9 3.7 3.4 12.4 13.8 15.4           Media           Dish TV         Buy         80 106 32 1.0 1.3 4.3 81.1 61.2 17.4 13.5 24.1 24.9 99.2           D B Corp         Buy         371 450 21 20.4 23.7 27.6 18.2 15.6 4.3 3.8 25.5 25.8 26.6           Den Net.         Neutral         91 90 -1 -8.6 -2.7 0.3 NM NM 1.7 1.8 -12.0 -5.3 0.7           Ent.Network         Neutral         815 928 14 11.4 13.4 21.7 71.3 61.0 4.5 4.2 6.7 7.2 10.7           Hind. Media         Buy         267 350 31 25.9 28.3 33.6 10.3 9.4 1.8 1.5 19.0 17.3 17.3           HT Media         Neutral         91 90 -2 7.4 7.9 8.1 12.3 11.5 0.8 0.8 7.1 6.9 6.4           Jagran Prak.         Buy         175 225 28 10.8 12.4 14.1 16.3 14.2 2.4 2.3 17.6 16.5 17.4           Music Broadcast         Buy         372 469 26 6.4 9.3 14.0 57.9 39.9 39.9 3.9 3.5 11.2 9.3 12.4           PVR         Buy         1,259 1,628 29 20.5 30.9 46.9 61.3 40.8 6.1 5.3 10.4 14.0 18.2           Siti Net.         Neutral         25 32 30 -1.8 -0.3 0.4 NM NM NM NM 3.4 3.6 -23.5 -4.1 6.2															
Media           Dish TV         Buy         80         106         32         1.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           D B Corp         Buy         371         450         21         20.4         23.7         27.6         18.2         15.6         4.3         3.8         25.5         25.8         26.6           Den Net.         Neutral         91         90         -1         -8.6         -2.7         0.3         NM         NM         1.7         1.8         -12.0         -5.3         0.7           Ent.Network         Neutral         815         928         14         11.4         13.4         21.7         71.3         61.0         4.5         4.2         6.7         7.2         10.7           Hind. Media         Buy         267         350         31         25.9         28.3         33.6         10.3         9.4         1.8         1.5         19.0         17.3         17.3           HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8 <t< td=""><td></td><td>Not Nated</td><td>213</td><td></td><td></td><td>10.7</td><td>21.0</td><td>23.7</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		Not Nated	213			10.7	21.0	23.7							
Dish TV         Buy         80         106         32         1.0         1.3         4.3         81.1         61.2         17.4         13.5         24.1         24.9         99.2           D B Corp         Buy         371         450         21         20.4         23.7         27.6         18.2         15.6         4.3         3.8         25.5         25.8         26.6           Den Net.         Neutral         91         90         -1         -8.6         -2.7         0.3         NM         NM         1.7         1.8         -12.0         -5.3         0.7           Ent.Network         Neutral         815         928         14         11.4         13.4         21.7         71.3         61.0         4.5         4.2         6.7         7.2         10.7           Hind. Media         Buy         267         350         31         25.9         28.3         33.6         10.3         9.4         1.8         1.5         19.0         17.3         17.3           HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8         0.8         7.1         6.9									27.1	24.7	3.7	3.4	12.7	13.0	13.4
D B Corp         Buy         371         450         21         20.4         23.7         27.6         18.2         15.6         4.3         3.8         25.5         25.8         26.6           Den Net.         Neutral         91         90         -1         -8.6         -2.7         0.3         NM         NM         1.7         1.8         -12.0         -5.3         0.7           Ent.Network         Neutral         815         928         14         11.4         13.4         21.7         71.3         61.0         4.5         4.2         6.7         7.2         10.7           Hind. Media         Buy         267         350         31         25.9         28.3         33.6         10.3         9.4         1.8         1.5         19.0         17.3         17.3           HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8         0.8         7.1         6.9         6.4           Jagran Prak.         Buy         175         225         28         10.8         12.4         14.1         16.3         14.2         2.4         2.3         17.6         16.5 </td <td></td> <td>Ruy</td> <td>80</td> <td>106</td> <td>32</td> <td>1.0</td> <td>1 2</td> <td>13</td> <td>Q1 1</td> <td>61.2</td> <td>17 <i>/</i>l</td> <td>13.5</td> <td>2/ 1</td> <td>2/1 0</td> <td>00.2</td>		Ruy	80	106	32	1.0	1 2	13	Q1 1	61.2	17 <i>/</i> l	13.5	2/ 1	2/1 0	00.2
Den Net.         Neutral         91         90         -1         -8.6         -2.7         0.3         NM         NM         1.7         1.8         -12.0         -5.3         0.7           Ent.Network         Neutral         815         928         14         11.4         13.4         21.7         71.3         61.0         4.5         4.2         6.7         7.2         10.7           Hind. Media         Buy         267         350         31         25.9         28.3         33.6         10.3         9.4         1.8         1.5         19.0         17.3         17.3           HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8         0.8         7.1         6.9         6.4           Jagran Prak.         Buy         175         225         28         10.8         12.4         14.1         16.3         14.2         2.4         2.3         17.6         16.5         17.4           Music Broadcast         Buy         372         469         26         6.4         9.3         14.0         57.9         39.9         3.9         3.5         11.2         9		-													
Ent.Network         Neutral         815         928         14         11.4         13.4         21.7         71.3         61.0         4.5         4.2         6.7         7.2         10.7           Hind. Media         Buy         267         350         31         25.9         28.3         33.6         10.3         9.4         1.8         1.5         19.0         17.3         17.3           HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8         0.8         7.1         6.9         6.4           Jagran Prak.         Buy         175         225         28         10.8         12.4         14.1         16.3         14.2         2.4         2.3         17.6         16.5         17.4           Music Broadcast         Buy         372         469         26         6.4         9.3         14.0         57.9         39.9         3.9         3.5         11.2         9.3         12.4           PVR         Buy         1,259         1,628         29         20.5         30.9         46.9         61.3         40.8         6.1         5.3         10.4	•	•													
Hind. Media         Buy         267         350         31         25.9         28.3         33.6         10.3         9.4         1.8         1.5         19.0         17.3         17.3           HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8         0.8         7.1         6.9         6.4           Jagran Prak.         Buy         175         225         28         10.8         12.4         14.1         16.3         14.2         2.4         2.3         17.6         16.5         17.4           Music Broadcast         Buy         372         469         26         6.4         9.3         14.0         57.9         39.9         3.9         3.5         11.2         9.3         12.4           PVR         Buy         1,259         1,628         29         20.5         30.9         46.9         61.3         40.8         6.1         5.3         10.4         14.0         18.2           Siti Net.         Neutral         25         32         30         -1.8         -0.3         0.4         NM         NM         NM         3.6         -23.5         -4.1 <td></td>															
HT Media         Neutral         91         90         -2         7.4         7.9         8.1         12.3         11.5         0.8         0.8         7.1         6.9         6.4           Jagran Prak.         Buy         175         225         28         10.8         12.4         14.1         16.3         14.2         2.4         2.3         17.6         16.5         17.4           Music Broadcast         Buy         372         469         26         6.4         9.3         14.0         57.9         39.9         3.9         3.5         11.2         9.3         12.4           PVR         Buy         1,259         1,628         29         20.5         30.9         46.9         61.3         40.8         6.1         5.3         10.4         14.0         18.2           Siti Net.         Neutral         25         32         30         -1.8         -0.3         0.4         NM         NM         3.4         3.6         -23.5         -4.1         6.2															
Jagran Prak.         Buy         175         225         28         10.8         12.4         14.1         16.3         14.2         2.4         2.3         17.6         16.5         17.4           Music Broadcast         Buy         372         469         26         6.4         9.3         14.0         57.9         39.9         3.9         3.5         11.2         9.3         12.4           PVR         Buy         1,259         1,628         29         20.5         30.9         46.9         61.3         40.8         6.1         5.3         10.4         14.0         18.2           Siti Net.         Neutral         25         32         30         -1.8         -0.3         0.4         NM         NM         3.4         3.6         -23.5         -4.1         6.2		-													
Music Broadcast         Buy         372         469         26         6.4         9.3         14.0         57.9         39.9         3.9         3.5         11.2         9.3         12.4           PVR         Buy         1,259         1,628         29         20.5         30.9         46.9         61.3         40.8         6.1         5.3         10.4         14.0         18.2           Siti Net.         Neutral         25         32         30         -1.8         -0.3         0.4         NM         NM         3.4         3.6         -23.5         -4.1         6.2															
PVR         Buy         1,259         1,628         29         20.5         30.9         46.9         61.3         40.8         6.1         5.3         10.4         14.0         18.2           Siti Net.         Neutral         25         32         30         -1.8         -0.3         0.4         NM         NM         3.4         3.6         -23.5         -4.1         6.2	_	-													
Siti Net. Neutral 25 32 30 -1.8 -0.3 0.4 NM NM 3.4 3.6 -23.5 -4.1 6.2		-													
		-													
Sun IV Neutral /15 860 20 24.9 28.5 35.9 28.7 25.1 6.8 6.3 23.6 25.0 28.8															
	Sun I V	neutral	/15	860	20	24.9	28.5	35.9	28.7	25.1	6.8	6.3	23.6	25.0	28.8



		CMP	TP	% Upside		EPS (INF	5)	P/F	(x)	P/	B (x)		ROE (%	)
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Zee Ent.	Buy	514	630	23	23.1	14.7	18.9	22.2	34.9	8.5	7.3	24.7	22.6	24.5
Aggregate								38.6	29.5	5.4	4.9	14.0	16.7	21.3
Metals														
Hindalco	Buy	231	309	34	16.2	22.0	26.3	14.3	10.5	1.8	1.5	14.0	15.3	15.4
Hind. Zinc	Neutral	287	301	5	19.7	22.6	26.9	14.6	12.7	3.9	4.2	24.4	32.0	35.1
JSPL	Buy	133	194	46	-20.9	-15.8	2.0	NM	NM	0.4	0.4	-7.9	-4.9	0.6
JSW Steel	Buy	240	297	24	14.8	21.9	25.7	16.2	10.9	2.6	2.1	17.3	21.3	20.8
Nalco	Neutral	70	63	-10	3.7	3.5	4.2	19.0	20.1	1.3	1.3	7.2	6.5	7.7
NMDC	Buy	123	180	46	10.0	12.4	12.1	12.4	9.9	1.7	1.6	12.8	15.2	15.6
SAIL	Sell	61	30	-51	-6.2	-7.7	-4.2	NM	NM	0.7	0.7	-6.7	-9.1	-5.3
Vedanta	Buy	300	316	5	15.1	24.8	33.1	19.8	12.1	1.8	1.7	9.7	14.8	18.4
Tata Steel	Neutral	633	591	-7	37.9	65.1	64.3	16.7	9.7	1.9	1.7	15.7	18.6	16.2
Aggregate				<u> </u>				20.1	13.8	1.6	1.6	8.2	11.4	13.3
Oil & Gas														
BPCL	Neutral	510	515	1	48.3	34.3	41.3	10.5	14.9	3.3	2.8	32.4	20.4	21.4
GAIL	Sell	384	346	-10	22.6	26.5	31.3	17.0	14.5	1.7	1.6	9.6	11.3	12.4
Gujarat Gas	Sell	795	691	-13	20.4	37.2	46.1	39.0	21.4	6.7	5.3	17.8	27.6	27.4
Gujarat St. Pet.	Neutral	197	171	-13	8.8	11.1	13.3	22.4	17.7	2.5	2.2	11.6	13.2	14.2
HPCL	Buy	458	510	11	40.7	34.1	36.3	11.3	13.4	3.4	2.9	32.4	23.6	21.7
IOC	Buy	426	458	7	43.0	36.7	40.4	9.9	11.6	2.0	1.8	21.2	16.0	15.8
IGL	Neutral	1,270	1,152	-9	44.0	49.9	56.3	28.9	25.5	6.1	5.1	21.0	21.9	20.9
MRPL	Sell	125	113	-10	14.8	9.4	11.7	8.5	13.3	2.2	1.9	31.4	15.5	17.0
Oil India	Buy	278	316	14	19.3	27.9	31.1	14.4	10.0	0.8	0.7	5.7	7.5	8.0
ONGC	Buy	160	195	22	16.4	16.5	19.7	9.7	9.7	0.9	0.9	10.1	9.4	10.9
PLNG	Buy	231	274	19	11.4	14.0	17.9	20.3	16.5	4.3	3.6	23.2	23.7	25.5
Reliance Ind.	Neutral	1,581	1,499	-5	96.7	115.5	128.1	16.4	13.7	1.6	1.5	11.6	12.3	12.3
Aggregate	Neatrai	1,001	1,177		70.7	110.0	120.1	12.6	12.6	1.7	1.5	13.3	12.2	12.7
Retail														
Jubilant Food	Sell	1,379	850	-38	10.0	14.8	20.7	137.9	93.1	11.3	10.4	8.2	11.1	14.0
Titan Co.	Neutral	608	565	-7	9.0	10.6	12.6	67.3	57.3	12.8	11.6	20.6	21.3	22.2
Aggregate								73.3	61.1	12.6	11.5	17.2	18.9	19.6
Technology														
Cyient	Buy	519	600	16	30.6	35.4	41.9	17.0	14.7	2.8	2.4	16.2	16.6	17.3
HCL Tech.	Neutral	878	950	8	59.8	61.8	65.9	14.7	14.2	3.7	3.3	27.5	24.9	23.8
Hexaware	Neutral	269	250	-7	13.7	15.7	16.5	19.6	17.1	4.8	4.1	26.5	25.7	23.1
Infosys	Buy	895	1,030	15	62.9	62.2	67.2	14.2	14.4	3.0	2.7	22.0	19.6	19.3
KPIT Tech	Neutral	113	140	24	11.9	10.6	13.1	9.5	10.7	1.4	1.3	14.3	13.0	14.2
L&T Infotech	Buy	743	880	19	55.5	60.2	68.0	13.4	12.3	4.7	3.6	40.4	33.0	29.4
Mindtree	Neutral	460	450	-2	24.9	28.7	32.9	18.5	16.0	3.0	2.9	16.8	17.3	20.1
Mphasis	Neutral	593	610	3	38.9	40.3	43.0	15.2	14.7	2.0	2.2	13.2	14.5	16.2
NIIT Tech	Neutral	495	540	9	38.0	42.3	48.7	13.0	11.7	1.7	1.6	13.7	14.4	15.4
Persistent Sys	Buy	617	750	22	37.7	43.3	52.0	16.4	14.2	2.5	2.4	17.0	17.9	20.7
Tata Elxsi	Buy	1,645	1,992	21	56.3	67.4	79.7	29.2	24.4	9.2	7.4	37.1	33.5	32.2
TCS	Neutral	2,493	2,350	-6	133.4	133.6	147.7	18.7	18.7	5.6	6.0	32.6	31.1	33.5
Tech Mah	Buy	430	490	14	30.9	34.0	36.8	13.9	12.7	2.3	2.1	18.4	17.4	16.9
Wipro	Neutral	291	270	-7	16.9	18.1	19.1	17.2	16.1	2.7	2.7	16.9	16.1	16.1
Zensar Tech	Buy	786	950	21	52.1	51.9	70.0	15.1	15.1	2.4	2.2	17.2	15.0	17.9
Aggregate	, 							16.6	16.5	3.8	3.7	22.9	22.8	22.0
Telecom														
Bharti Airtel	Buy	432	490	13	11.1	4.3	6.6	38.9	99.5	2.6	2.5	6.7	2.5	3.8
Bharti Infratel	Buy	383	480	25	14.9	17.9	20.4	25.8	21.4	4.6	3.9	16.2	19.8	19.4
Idea Cellular	Buy	91	110	21	-1.1	-10.9	-11.3	NM	NM	1.3	1.6	-1.6	-17.3	-21.7
Tata Comm	Buy	638	775	22	27.2	8.7	26.1	23.4	73.2	11.4	9.9	132.2	14.5	33.6
Aggregate	~ ~ <u>J</u>		,,,		_,,_	3.7	_0.1	38.5	213.3	2.7	2.7	6.9	1.2	2.8
Audredate														



		CMP	TP	% Upside		EPS (INF	?)	P/I	E (x)	P/I	B (x)		ROE (%)	)
Company	Reco	(INR)	(INR)	Downside	FY17	FY18E	FY19E	FY17	FY18E	FY17	FY18E	FY17	FY18E	FY19E
Coal India	Buy	241	275	14	14.9	18.3	19.1	16.1	13.2	6.1	5.8	37.8	44.2	44.2
CESC	Buy	940	1,360	45	51.9	88.9	99.3	18.1	10.6	1.2	1.1	6.5	10.6	10.8
JSW Energy	Sell	61	49	-20	3.8	3.4	2.7	16.0	18.1	1.0	1.0	6.3	5.3	4.2
NTPC	Buy	170	204	20	13.0	13.3	16.3	13.1	12.8	1.4	1.3	11.5	10.8	12.4
Power Grid	Buy	219	262	19	14.2	17.4	20.6	15.4	12.6	2.3	2.0	16.2	17.3	17.8
Tata Power	Sell	79	68	-14	5.2	6.4	6.7	15.3	12.4	1.8	1.6	11.2	13.9	12.1
Aggregate								14.8	12.8	2.2	2.0	14.9	15.9	16.6
Others														
Arvind	Neutral	364	375	3	12.4	12.9	18.6	29.4	28.1	2.6	2.5	10.3	9.1	12.0
Avenue Supermart	sNeutral	989	882	-11	7.7	12.7	17.6	128.9	77.8	16.1	14.0	17.9	19.3	23.0
Bata India	Under Review	679	-		13.5	15.7	19.4	50.3	43.2	6.6	5.9	13.9	14.4	15.8
Castrol India	Buy	389	527	36	13.6	14.4	15.0	28.5	26.9	32.3	28.9	115.2	113.3	106.1
Century Ply.	Neutral	260	323	24	8.7	9.8	12.9	29.9	26.5	8.1	6.7	31.1	27.7	29.6
Coromandel Intl	Buy	423	523	24	16.6	24.1	29.0	25.4	17.5	4.3	3.7	17.5	22.5	23.4
Delta Corp	Buy	182	237	30	3.1	5.8	7.9	59.6	31.5	4.6	3.1	8.1	12.3	12.6
Dynamatic Tech	Buy	2,128	3,334	57	67.6	112.9	166.7	31.5	18.8	4.3	3.5	15.1	20.7	24.3
Eveready Inds.	Buy	295	358	22	12.9	13.6	16.3	22.9	21.6	7.4	6.0	37.7	30.8	30.1
Interglobe	Neutral	1,217	1,312	8	46.0	63.9	93.7	26.4	19.0	21.7	19.3	86.2	107.5	137.7
Indo Count	Neutral	109	129	18	13.0	8.9	10.8	8.4	12.3	2.5	2.1	34.8	18.6	18.3
Info Edge	Buy	948	1,130	19	15.7	21.8	24.7	60.5	43.6	5.8	5.3	10.2	12.7	13.1
Inox Leisure	Sell	233	240	3	3.3	8.0	12.0	69.8	29.0	4.0	3.6	5.9	12.5	16.2
Jain Irrigation	Under Review	95	-		5.5	7.6	10.0	17.1	12.5	1.5	1.4	8.6	11.7	14.8
Just Dial	Neutral	359	465	29	17.5	18.5	21.1	20.6	19.5	2.8	2.5	14.8	13.4	13.7
Kaveri Seed	Buy	544	738	36	19.1	34.0	41.0	28.5	16.0	3.7	3.9	13.6	23.3	27.4
Kitex Garm.	Buy	231	394	71	18.6	22.1	26.2	12.4	10.4	3.3	2.7	29.8	28.6	27.6
Manpasand	Buy	831	926	11	12.7	20.2	30.9	65.5	41.2	4.1	3.8	7.3	8.5	13.5
MCX	Buy	1,011	1,300	29	24.8	28.0	42.2	40.7	36.1	3.8	3.6	10.2	10.2	14.5
Monsanto	Buy	2,474	3,295	33	86.2	105.1	126.7	28.7	23.5	8.1	7.3	31.6	32.5	34.5
Navneet Education	n Buy	157	226	44	7.8	9.4	11.3	20.2	16.6	5.0	4.3	26.8	27.8	28.2
PI Inds.	Buy	736	894	21	33.4	30.4	35.8	22.1	24.2	6.2	5.2	32.8	23.4	22.9
Piramal Enterp.	Buy	2,625	3,044	16	72.6	104.1	144.6	36.2	25.2	3.4	3.1	9.8	13.0	16.4
SRF	Buy	1,465	1,648	13	85.9	80.2	103.0	17.0	18.3	2.7	2.4	16.6	13.7	16.0
S H Kelkar	Buy	247	298	21	7.2	7.6	9.9	34.1	32.5	4.4	4.0	13.7	12.9	15.2
Symphony	Sell	1,249	1,288	3	23.7	35.1	42.9	52.8	35.6	19.6	17.3	43.3	51.6	54.5
Trident	Buy	87	114	32	6.6	8.3	10.4	13.1	10.5	1.6	1.4	13.0	14.5	16.1
TTK Prestige	Neutral	6,371	5,281	-17	132.1	137.8	176.1	48.2	46.2	8.7	7.9	19.5	18.0	20.7
V-Guard	Neutral	183	167	-9	3.6	4.5	6.0	51.1	40.8	12.2	10.0	27.4	26.9	28.8
Wonderla	Buy	335	393	17	7.0	11.9	16.0	47.9	28.0	4.4	3.9	9.5	14.8	17.5





# MOSL Universe stock performance

Company	1 Day (%)	1M (%)	12M (%)
Automobiles	1 Day (%)	1101 (70)	12111 (70)
Amara Raja	0.9	-8.8	-14.0
Ashok Ley.	2.4	-0.4	17.0
Bajaj Auto	0.7	-1.9	-4.0
Bharat Forge	2.5	2.8	35.6
Bosch	-0.3	-9.0	-7.4
CEAT	2.6	-9.6	95.9
Eicher Mot.	-1.1	6.2	39.3
Endurance Tech.	-0.9	7.8	07.0
Escorts	2.2	-6.5	88.0
Exide Ind	0.9	-8.1	13.8
Hero Moto	0.1	5.7	17.7
M&M	-0.1	-0.7	-4.8
Mahindra CIE	-1.4	-2.2	31.4
Maruti Suzuki	1.0	0.6	56.7
Tata Motors	1.8	-18.2	-24.5
TVS Motor	0.3	2.4	90.3
Banks - Private	0.0	2. 1	70.0
Axis Bank	0.8	-6.9	-13.6
DCB Bank	3.3	-6.1	57.2
Equitas Hold.	1.4	-6.2	-12.8
Federal Bank	1.2	-9.2	58.7
HDFC Bank	1.3	4.1	41.6
ICICI Bank	1.7	-0.9	31.2
IDFC Bank	2.4	-7.9	3.9
IndusInd	2.2	5.9	39.7
J&K Bank	0.5	-4.1	13.7
Kotak Mah. Bk	1.1	-1.8	26.1
RBL Bank	1.6	-4.0	20.1
South Indian	2.1	-5.1	33.9
Yes Bank	0.5	9.1	28.3
Banks - PSU	0.0	7.1	20.0
BOB	1.1	-12.9	-14.2
BOI	3.1	-7.2	25.3
Canara	2.8	-4.2	30.2
IDBI Bk	1.6	-7.5	-24.1
Indian Bk	2.7	-9.4	30.9
OBC	3.2	-17.6	3.7
PNB	3.3	-10.0	12.4
SBI	1.7	-4.0	9.5
Union Bk	3.8	-13.2	-1.0
NBFCs			
Bajaj Fin.	5.7	10.0	77.5
Bharat Fin.	4.5	13.7	17.0
Capital First	3.4	-5.5	-0.1
Cholaman.Inv.&Fn	0.4	0.8	5.4
Dewan Hsg.	2.6	2.1	72.0
GRUH Fin.	-0.8	5.7	58.5
HDFC	0.7	7.4	28.1
Indiabulls Hsg	3.4	6.9	51.2
L&T Fin.Holdings	2.3	13.4	82.6
LIC Hsg Fin	3.7	-10.8	19.7
Manappuram	1.5	-11.4	7.3
M&M Fin.	1.5	16.1	24.5
Muthoot Fin	0.2	-1.8	33.0
PFC	3.1	-6.2	0.6
Repco Home	2.6	-18.9	-20.9
REC	2.8	-13.9	35.7
STF	1.4	0.9	-23.1
Shriram City Union	1.0	-5.6	-0.4
2 2 511, 5111011	1.0	0.0	

Company	1 Day (0/)	11/1/0/1	121/1/0/\
Company	1 Day (%)	1M (%)	12M (%)
Capital Goods	0.0	7.0	17.0
ABB	0.2	-7.3	17.9
Bharat Elec.	2.6	6.8	50.0
BHEL	1.7	-12.1	-6.9
Blue Star	0.4	8.7	51.1
CG Cons. Elec.	-1.3	4.9	29.8
CG Power & Inds Sol.	1.8	-6.4	-7.3
Cummins	-1.6	-12.5	-0.4
GE T&D	0.0	18.0	20.8
Havells	1.0	3.1	15.9
K E C Intl	0.6	1.9	119.3
L&T	0.5	-4.6	14.3
Pennar Eng.	1.1	-23.2	-47.3
Siemens	-0.6	-7.6	-2.4
Solar Ind	0.1	-4.0	39.3
Suzlon Energy	2.2	-14.4	-0.6
Thermax	-0.5	-5.9	4.6
Va Tech Wab.	-0.8	-0.7	5.7
Voltas	-0.6	4.7	40.2
Cement			
Ambuja Cem.	1.1	4.1	2.0
ACC	0.8	5.4	8.9
Birla Corp.	1.0	0.8	44.7
Dalmia Bharat	1.4	-1.8	72.6
Grasim Inds.	0.7	5.5	48.3
India Cem	2.2	-14.6	27.1
J K Cements	-0.1	3.0	28.9
JK Lakshmi Ce	0.8	-10.4	-5.9
Ramco Cem	0.2	-1.4	21.1
Orient Cem	0.3	-5.6	-12.7
Prism Cem	2.8	-9.3	-3.1
Shree Cem	0.1	-2.9	2.5
Ultratech	-0.3	-5.1	3.6
Consumer			
Asian Paints	0.9	-1.3	1.4
Britannia	1.2	10.9	26.8
Colgate	0.3	1.5	16.0
Dabur	-0.8	-1.4	2.5
Emami	-1.1	-1.3	-4.8
Godrej Cons.	1.9	-5.7	20.7
GSK Cons.	-0.2	-2.2	-14.9
HUL	-1.1	2.5	28.8
ITC	-0.3	-2.2	12.3
Jyothy Lab	-0.5	-3.1	27.7
Marico	0.3	-4.1	9.0
Nestle	0.1	-2.8	-2.7
Page Inds	0.2	2.5	20.5
Parag Milk	0.3	-6.2	-24.3
Pidilite Ind.	-0.2	1.4	15.9
P&G Hygiene	0.4	1.3	21.0
Prabhat Dairy	1.2	-2.8	55.1
United Brew	0.2	-1.1	1.2
United Spirits	-1.0	-8.7	7.4
Healthcare			
Alembic Phar	-1.2	-6.4	-21.3
Alkem Lab	2.7	1.4	19.5
Ajanta Pharma	3.5	-18.6	-39.7
Aurobindo	0.4	-6.6	-5.1
Biocon	0.7	-17.5	12.2
Cadila	-1.3	-12.4	24.4
Cipla	0.1	-1.1	0.8
- I			





# MOSL Universe stock performance


Company	1 Day (%)	1M (%)	12M (%)
Divis Lab	1.4	-11.4	-51.4
Dr Reddy's	2.2	-26.5	-32.5
Fortis Health	7.7	-6.8	-16.0
Glenmark	0.0	-13.7	-29.1
Granules	0.6	-9.8	1.0
GSK Pharma	1.0	-6.2	-22.6
IPCA Labs	0.3	-14.3	-19.6
Jubilant Life	1.6	-3.8	42.7
Lupin	1.1	-16.5	-38.6
Sanofi India	0.1	-4.3	-7.5
Shilpa Medicare	0.6	-19.0	-3.2
Strides Shasun	0.3	-15.3	-4.5
Sun Pharma	-0.4	-18.7	-38.5
Syngene Intl	-0.5	-8.9	3.5
Torrent Pharma	-1.2	-5.0	-23.5
Logistics			
Allcargo Logistics	1.8	-7.0	-13.4
Blue Dart	0.7	-7.6	-24.1
Concor	-1.2	6.9	16.7
Gateway Distriparks	0.5	-13.5	-15.2
Gati	5.6	-8.2	-25.9
Transport Corp.	0.0	-14.9	28.9
Media			
Dish TV	1.3	2.6	-16.6
D B Corp	-2.4	-1.4	-9.1
Den Net.	8.0	14.9	3.2
Ent.Network	1.8	-10.6	15.0
Hind. Media	-1.8	-5.5	-1.5
HT Media	-0.4	7.7	16.8
Jagran Prak.	-0.3	0.2	-5.2
Music Broadcast	1.3	1.7	
PVR	-0.9	-7.8	7.0
Siti Net.	-1.6	-5.0	-32.2
Sun TV	2.3	-11.3	53.7
Zee Ent.	-0.5	-7.3	0.0
Metals			
Hindalco	1.2	7.8	48.7
Hind. Zinc	-0.2	2.3	26.1
JSPL	3.2	-2.6	52.3
JSW Steel	3.3	11.8	36.1
Nalco	0.2	-1.3	47.1
NMDC	1.0	0.3	12.9
SAIL	3.2	-2.7	21.6
Vedanta	2.2	11.7	72.0
Tata Steel	2.3	14.6	64.3
Oil & Gas	2.3	9	55
BPCL	0.0	9.1	32.5
GAIL	2.0	1.9	39.6
Gujarat Gas	3.5	4.3	20.0
Gujarat St. Pet.	4.7	13.5	35.0
HPCL	1.7	24.7	79.2
IOC	0.7	12.0	56.9
IGL	0.8	11.1	67.7
MRPL	1.5	-0.8	56.7
Oil India	0.9	-0.6	-0.1
ONGC	0.9	-3.0	0.5
PLNG	0.2	12.3	38.0
Reliance Ind.	1.1	-0.3	56.6
	1.1	-0.3	30.0
Retail Jubilant Food	1.5	10.1	12.2
			49.9
Titan Co.	-1.2	12.0	49.9


Company	1 Day (%)	1M (%)	12M (%)
Technology	-		
Cyient	1.1	-2.2	0.8
HCL Tech.	0.3	-2.9	11.3
Hexaware	1.7	10.4	22.9
Infosys	2.0	-8.7	-13.9
KPIT Tech	2.8	-10.4	-16.5
L&T Infotech	0.0	-3.2	15.0
Mindtree	1.0	-4.8	-18.6
Mphasis	0.6	2.8	11.8
NIIT Tech	2.2	-8.7	20.0
Persistent Sys	-0.4	-6.0	-4.4
Tata Elxsi	1.8	-2.1	1.5
TCS	-0.1	0.1	-4.2
Tech Mah	-2.1	8.8	-7.7
Wipro	0.2	1.6	12.0
Zensar Tech	0.5	-5.3	-27.0
Telecom			
Bharti Airtel	2.4	5.0	22.1
Bharti Infratel	-1.1	-6.7	10.6
Idea Cellular	3.0	-1.5	-10.2
Tata Comm	3.8	-2.8	27.9
Utiltites			
Coal India	0.4	-8.1	-28.4
CESC	0.7	4.6	44.0
JSW Energy	0.3	-8.5	-22.0
NTPC	1.4	3.3	6.9
Power Grid	-0.1	1.8	20.5
Tata Power	-1.4	-5.4	5.4
Others			
Arvind	0.7	-1.7	16.0
Avenue Super.	3.4	8.2	
Bata India	-0.5	17.1	24.8
Castrol India	0.2	-5.1	-6.8
Century Ply.	2.5	-9.6	17.9
Coromandel Intl	0.2	-2.3	56.3
Delta Corp	5.4	6.4	25.1
Dynamatic Tech	-0.6	-10.6	-28.5
Eveready Inds.	-0.9	-10.2	9.3
Interglobe	-1.2	-2.0	35.8
Indo Count	8.9	-29.5	-31.2
Info Edge	0.8	-6.0	13.9
Inox Leisure	1.0	-14.7	-12.3
Jain Irrigation	1.7	-13.0	13.6
Just Dial	-1.1	-5.8	-21.9
Kaveri Seed	2.4	-14.8	44.5
Kitex Garm.	-0.2	-14.7	-32.3
Manpasand	1.2	8.1	15.1
MCX	3.1	-10.4	1.4
Monsanto	1.3	-9.0	1.9
Navneet Educat.	1.1	-9.0	50.8
PI Inds.	1.5	-3.2	-6.0
Piramal Enterp.	1.8	-10.0	31.6
SRF	0.2	-3.1	-11.8
S H Kelkar	0.5	-8.7	-15.7
Symphony	1.0	-7.4	8.5
Trident	5.9	0.5	88.3
TTK Prestige	0.0	-0.3	29.4
V-Guard	1.2	0.9	48.3
Wonderla	-0.2	-6.5	-18.5
			. 5.0



# NOTES

# THEMATIC/STRATEGY RESEARCH GALLERY





















# **REPORT GALLERY**


# RECENT INITIATING COVERAGE REPORTS























# **DIFFERENTIATED PRODUCT GALLERY**













#### Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Securities Ltd. (MOSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOSL is a subsidiary company of Motilal Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Metropolitan Stock Exchange Of India Ltd. (MSE) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products. Details of associate entities of Motilal Oswal Securities Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

#### Pending Regulatory Enquiries against Motilal Oswal Securities Limited by SEBI:

SEBI pursuant to a complaint from client Shri C.R. Mohanraj alleging unauthorized trading, issued a letter dated 29th April 2014 to MOSL notifying appointment of an Adjudicating Officer as per SEBI regulations to hold inquiry and adjudge violation of SEBI Regulations; MOSL requested SEBI to provide all documents, records, investigation report relied upon by SEBI which were referred in Show Cause Notice and also sought personal hearing. The matter is currently pending.

MOSL, it's associates, Research Analyst or their relative may have any financial interest in the subject company. MOSL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. MOSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(les) discussed herein or act as an advisor or lender/borrower to such company(les) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer, etc. in the subject company in the last 12 month period. MOSL and/or its associates may have received any compensation from the subject company in the past

In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, MOSL or any of its associates may have:
a) managed or co-managed public offering of securities from subject company of this research report,

- managed of commanaged public offering of securities in assignment and in assignment assignment and in assignment c)
- Subject Company may have been a client of MOSL or its associates during twelve months preceding the date of distribution of the research report.

MOSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report. To enhance transparency, MOSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

#### Terms & Conditions:

This report has been prepared by MOSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOSL will not treat recipients as customers by virtue of their receiving this report.

### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Companies where there is interest

No

§ Analyst ownership of the stock A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.co trading desk of MOSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional"). investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account

#### For Singapore

Motifal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motifal Oswal Securities Limited in India. This research is distributed in Singapore by Motifal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 3080 1000. Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-30801085.

Registration details of group entities.: MOSL: NSE (Cash): INB231041238; NSE (F&O): INF231041238; NSE (CD): INE231041238; BSE (Cash): INB011041257; BSE(F&O): INF011041257; BSE(CD); MSE(Cash): INB261041231; MSE(F&O): INF261041231; MSE(CD): INF261041231